<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Therapeutic use and toxicity of high-dose methotrexate</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Therapeutic use and toxicity of high-dose methotrexate</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Therapeutic use and toxicity of high-dose methotrexate</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ann S LaCasce, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert Maki, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Arnold S Freedman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alberto S Pappo, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 01, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Folate antagonists were among the first antineoplastic agents to be developed. In 1948, aminopterin was used to induce remission in childhood acute lymphoblastic leukemia (ALL), and the related agent <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> (MTX) is still an important component of modern treatment for ALL as well as a number of other hematologic malignancies [<a href="#rid1">1</a>]. MTX was the first drug shown to cure a cancer when given as monotherapy, and single agent MTX remains a cornerstone of treatment for malignant gestational trophoblastic disease [<a href="#rid2">2</a>].</p><p>The broad range of antitumor activity seen with MTX is reflected in the large number of malignant conditions for which MTX is a component of the treatment regimen  (<a class="graphic graphic_table graphicRef60020" href="/z/d/graphic/60020.html" rel="external">table 1</a>). Furthermore, in addition to antiproliferative activity, MTX also has anti-inflammatory and immunomodulating properties, leading to its use in a wide range of doses for a broad range of therapeutic indications across multiple specialties  (<a class="graphic graphic_table graphicRef76707" href="/z/d/graphic/76707.html" rel="external">table 2</a>).</p><p>This topic review will cover the clinical use of high-dose MTX for treatment of malignancy, focusing on the prevention and management of toxicity. Intrathecal use of MTX and clinical use of low-dose and intermediate-dose MTX for both malignant and nonmalignant (eg, rheumatologic) conditions are covered elsewhere. (See appropriate topic reviews.)</p><p class="headingAnchor" id="H2"><span class="h1">DEFINITION OF HIGH-DOSE METHOTREXATE</span><span class="headingEndMark"> — </span>The side effect profile of MTX varies markedly according to dose. Regimens containing MTX are classified as high, intermediate, or low-dose:</p><p class="bulletIndent1"><span class="glyph">●</span>Most clinicians reserve the term high-dose MTX (HDMTX) for doses ≥500 mg/m<sup>2</sup>, as are used for central nervous system (CNS) prophylaxis in patients with leukemia and high-risk lymphoma, and for the treatment of leptomeningeal metastases, primary CNS lymphoma, and osteosarcoma. These regimens deliver an otherwise lethal dose of MTX in a 4 to 36 hour infusion, and require a two to three day period of multiple <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> doses to terminate the toxic effect of MTX (termed leucovorin "rescue"). Successful rescue by leucovorin depends on rapid elimination of MTX by the kidneys, which requires aggressive pretreatment as well as posttreatment hydration and urinary alkalinization. The main toxicities of HDMTX are elevated serum transaminase levels and renal insufficiency, which can delay drug clearance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Doses between 50 and 500 mg/m<sup>2</sup>, as used for malignant gestational trophoblastic disease (GTD), are considered intermediate-dose MTX. In general, these patients do not require aggressive hydration or urinary alkalinization. <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">Leucovorin</a> rescue is rarely needed with doses ≤250 mg/m<sup>2</sup> unless unexpected toxicity is encountered. (See  <a class="medical medical_review" href="/z/d/html/3242.html" rel="external">"Initial management of low-risk gestational trophoblastic neoplasia", section on 'Methotrexate as the preferred option'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Low-dose MTX (&lt;50 mg/m<sup>2</sup>) is used intravenously for the treatment of bladder and breast cancer and desmoid tumors, and orally for patients with T-cell large granular lymphocyte (LGL) leukemia, ALL, acute promyelocytic leukemia, mycosis fungoides, and various nonmalignant immune-mediated disorders  (<a class="graphic graphic_table graphicRef76707" href="/z/d/graphic/76707.html" rel="external">table 2</a>).</p><p></p><p>The side effect profile of chronic low-dose oral MTX, as used for the treatment of nonmalignant disorders, differs from that of cyclical parenteral administration in the setting of cancer, particularly with regard to myelosuppression, hepatic fibrosis, and pulmonary toxicity. The major side effects of low-dose oral MTX for nonmalignant disorders are addressed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7509.html" rel="external">"Major side effects of low-dose methotrexate"</a>.)</p><p>Low doses of MTX (typically 12 mg total dose) also can be given intrathecally for treatment of leptomeningeal metastases or CNS prophylaxis in patients with leukemia or high-risk lymphoma. In this setting, the major toxicities are neurologic; there is a very small risk of myelosuppression because MTX is eliminated from the cerebrospinal fluid by slow passive diffusion into the systemic circulation. Because of this, some experts recommend a short course of <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> rescue in this situation, particularly for patients with renal dysfunction. (See  <a class="medical medical_review" href="/z/d/html/5184.html" rel="external">"Treatment of leptomeningeal disease from solid tumors"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">CLINICAL PHARMACOLOGY</span><span class="headingEndMark"> — </span>MTX enters the cell via the same energy-dependent, saturable carrier protein that transports naturally occurring folates and <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> [<a href="#rid3">3-6</a>]. Some tumors have reduced or no transport capability; in such cases, high extracellular concentrations of MTX permit the drug to enter the cell by passive diffusion [<a href="#rid7">7,8</a>]. A third mechanism of MTX entry is through endocytosis, mediated by folate binding proteins, which may be overexpressed in malignant as compared with normal cells [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Mechanism of action</span></p><p class="headingAnchor" id="H69716673"><span class="h3">Interference with folate metabolism</span><span class="headingEndMark"> — </span>The antiproliferative activity of antifolates such as MTX results from interference with folate metabolism. A normal dividing cell uses large amounts of reduced folates to maintain ongoing purine and thymidine synthesis  (<a class="graphic graphic_figure graphicRef52756" href="/z/d/graphic/52756.html" rel="external">figure 1</a>); demand is even greater for rapidly dividing malignant cells.</p><p>Several key enzymes of these synthetic pathways are targets of MTX:</p><p class="bulletIndent1"><span class="glyph">●</span>The critical factor for the cell's ongoing production of thymidylate, and to a lesser extent the purines, is its ability to regenerate reduced folates from the oxidized forms. The key enzyme in this process is dihydrofolate reductase (DHFR), which converts dihydrofolate to tetrahydrofolate, thus continuously replenishing the cell's supply of reduced folates. Competitive inhibition of DHFR represents the main mechanism of action for antifolates such as MTX, but other synthetic enzymes are also inhibited by polyglutamated forms of MTX. (See <a class="local">'Importance of polyglutamation'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Within the thymidine synthetic pathway, the enzyme thymidylate synthetase (TS) uses a methyl group from the reduced folate, 5-methylenetetrahydofolate, to synthesize deoxythymidylate monophosphate (dTMP) from deoxyuridylate monophosphate (dUMP).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Within the purine synthetic pathway, the enzymes glycinamide ribonucleotide transformylase (GARFT) and aminoimidazole carboxamide transformylase (AICARFT) both use the formyl groups of the reduced folate N(10)-formyltetrahydrofolate to initiate synthesis of adenosine and guanosine.</p><p></p><p>Intracellularly, MTX competitively inhibits DHFR because it has a higher affinity for the enzyme than the naturally occurring dihydrofolate. The depletion of reduced folates (tetrahydrofolates) causes an abrupt cessation of thymidine synthesis, DNA synthesis, and eventually cell death. This process is accentuated in rapidly dividing cells (ie, those in the S-phase of the cell cycle), which require more DNA precursors. As a result, MTX is considered an S-phase specific cytotoxic drug.</p><p>The level of DHFR in any given cell is in great excess of what is needed to provide normal levels of reduced folates [<a href="#rid3">3</a>]. Furthermore, tetrahydrofolate synthesis continues until more than 95 percent of DHFR activity has been inhibited [<a href="#rid7">7</a>]. As a result, high levels of MTX are required to successfully compete with other folates for DHFR binding [<a href="#rid7">7,9,10</a>].</p><p class="headingAnchor" id="H5"><span class="h4">Importance of polyglutamation</span><span class="headingEndMark"> — </span>As part of normal cellular physiology, multiple glutamate residues are added to carboxyfolates by the enzyme folyl polyglutamate synthetase (FPGS), a process referred to as polyglutamation  (<a class="graphic graphic_figure graphicRef52756" href="/z/d/graphic/52756.html" rel="external">figure 1</a>). Polyglutamation increases the intracellular pool of folates, as polyglutamated folates are not easily transported out of the cell because of their size and charge. Folate polyglutamation also influences the equilibrium balance in favor of continual cellular uptake of folates [<a href="#rid5">5,11</a>].</p><p>When significant intracellular levels are present, MTX is polyglutamated by the same enzyme [<a href="#rid12">12</a>]. However, in most cell lines studied, conversion to polyglutamated MTX (PGMTX) does not occur until cells have been exposed to the drug for at least six hours at concentrations of at least 2 micromoles/liter (2 microM, 2 X 10 [-6] M) [<a href="#rid8">8,9</a>]. These concentrations are easily achievable in plasma with high-dose MTX (HDMTX) but not with intermediate or low-dose regimens.</p><p>The accumulation of PGMTX metabolites serves to further amplify and prolong the antiproliferative effects of MTX:</p><p class="bulletIndent1"><span class="glyph">●</span>Intracellular accumulation and decreased efflux of PGMTX enhances and prolongs inhibition of DHFR, since PGMTX is less readily dissociable from the enzyme than is free MTX [<a href="#rid8">8,10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Polyglutamated forms of MTX also bind to other enzymes involved in DNA synthesis such as TS, AICARFT, and GARFT; this further depletes intracellular thymidine and inhibits purine synthesis [<a href="#rid13">13-15</a>]. Inhibition of TS also leads to accumulation of dUMP, which cannot be incorporated into DNA, further disrupting DNA synthesis and repair [<a href="#rid16">16</a>].</p><p></p><p>Besides being a main determinant of antitumor activity, MTX polyglutamation is also thought to be mainly responsible for the greater incidence and severity of all HDMTX-related side effects when there is prolonged MTX excretion or if <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> rescue is delayed beyond 36 hours [<a href="#rid10">10,16-18</a>]. Higher plasma MTX concentrations and longer exposure times increase the formation of longer polyglutamated MTX molecules [<a href="#rid8">8,13,19,20</a>]. When the polyglutamated tail has a larger number of glutamic acid residues (ie, greater than five), there is greater affinity for DHFR and TS, and degradation and diffusion out of the cell is slowed [<a href="#rid13">13,14</a>].</p><p>Finally, variability in polyglutamation between tumor cells and normal (nonmalignant) cells is thought to provide at least part of the explanation for why <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> can selectively rescue normal cells from the effects of HDMTX but does not compromise tumor cell cytotoxicity.</p><p class="headingAnchor" id="H69716653"><span class="h3">Other mechanisms</span><span class="headingEndMark"> — </span>In addition to involvement of pathways involved in folate metabolism, newer data suggest that upregulation of mitochondrial enzymes involved in the metabolism of serine and glycine may also influence tumor cell sensitivity to MTX [<a href="#rid21">21</a>]. Whether this finding is relevant to all tumors, especially osteosarcoma, is unclear.</p><p class="headingAnchor" id="H6"><span class="h3">Rationale for leucovorin rescue</span><span class="headingEndMark"> — </span>As with many other anticancer drugs, MTX has little selectivity for tumor cells, and its effectiveness is limited by toxicity to normal tissue, particularly the gastrointestinal (GI) epithelium and bone marrow. To improve the therapeutic index of MTX, Goldin developed the concept of rescuing normal cells from toxicity by providing reduced folates (<a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a>, also called folinic acid, N5-formyl-tetrahydrofolate, citrovorum factor) to bypass the metabolic block induced by MTX [<a href="#rid22">22</a>]. In these pioneering experiments, administration of leucovorin within 24 to 36 hours after administration of MTX was able to prevent MTX-induced host toxicity without diminishing antitumor activity.</p><p>The reason why <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> selectively rescues normal but not malignant cells is incompletely understood. The original premise that providing reduced folate would circumvent the metabolic block produced by MTX is not easily explained except in situations where folate transport is deficient in the malignant cells. In such cases, leucovorin cannot be transported into the malignant cell, but it can enter normal cells and compete with MTX for binding sites on DHFR because they retain a normal folate carrier protein [<a href="#rid6">6,23</a>]. If leucovorin is present in sufficient quantities, the enzyme is reactivated, and purine and thymidine synthesis can be reinitiated. This situation is thought to be relatively uncommon.</p><p>As noted above, cellular differences in polyglutamation have been suggested as an alternative explanation for selective <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> rescue. Intracellularly, leucovorin is able to compete with free but not polyglutamated MTX for binding to DHFR [<a href="#rid23">23</a>]. In contrast to tumor cells, comparatively little PGMTX synthesis occurs in normal gut epithelium and bone marrow precursors under similar conditions [<a href="#rid18">18,24</a>]. It is hypothesized that because of the lower levels of intracellular PGMTX, leucovorin can more effectively curtail DHFR inhibition in normal as compared with malignant cells [<a href="#rid11">11,14,18,24-26</a>].</p><p><a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">Leucovorin</a> can only rescue normal cells that have not already had lethal DNA damage from the toxic effects of MTX. Thus, to be effective, treatment with leucovorin must be initiated within 24 to 36 hours of starting HDMTX [<a href="#rid7">7</a>]. Issues relevant to the dose, route of administration, and duration of leucovorin rescue after HDMTX are discussed below. (See <a class="local">'Leucovorin administration'</a> below.)</p><p class="headingAnchor" id="H7"><span class="h3">Resistance to methotrexate</span><span class="headingEndMark"> — </span>Neoplastic cells may be innately resistant or acquire resistance to MTX. As an example, MTX is not a useful agent for treatment of acute myeloid leukemia because the leukemic cells cannot polyglutamate the drug once it enters the cell [<a href="#rid27">27</a>].</p><p>More often resistance is acquired through one or more of the following mechanisms [<a href="#rid3">3,27-29</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Decreased drug transport due to gene mutations or a change in the rate of transcription of the folate carrier</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased DHFR activity, typically due to gene amplification</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mutations in the DHFR protein, which decrease its affinity for MTX</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Decreased cellular polyglutamation of MTX due to increased folyl polyglutamate hydrolase activity or decreased FPGS activity</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Decreased TS activity or affinity for the folate antagonists</p><p></p><p>Because of the frequent development of acquired resistance, MTX is not typically used as a single agent for treatment of aggressive malignancy with the exception of primary CNS lymphoma, head and neck cancer, and malignant GTD. (See  <a class="medical medical_review" href="/z/d/html/3242.html" rel="external">"Initial management of low-risk gestational trophoblastic neoplasia"</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Pharmacokinetics, metabolism, and excretion</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacokinetics</strong> – Even when given identical doses of HDMTX, patients vary significantly in their pharmacokinetics, patterns of toxicity and in response to therapy. This diversity can, to some extent, be linked to sequence variations in genes involved in drug absorption, metabolism, excretion, cellular transport, and/or effector targets or target pathways [<a href="#rid30">30</a>]. A review of advances in the individual prediction of MTX toxicity and the impact of genetic polymorphisms on MTX efficacy and toxicity is beyond the scope of this review. (See  <a class="medical medical_review" href="/z/d/html/2904.html" rel="external">"Overview of pharmacogenomics", section on 'Drug transport'</a>.)</p><p></p><p class="bulletIndent1">Following intravenous (IV) administration, MTX is widely distributed through the body. In the serum, approximately 50 percent is protein/albumin-bound [<a href="#rid10">10</a>]. Peak serum levels following MTX doses &gt;1000 mg/m<sup>2</sup> are in the range of 500 to 1500 microM (50 to 150 X 10 [-5] M) [<a href="#rid31">31</a>]. The overall half-life following IV administration is between 8 and 12 hours.</p><p></p><p class="bulletIndent1">The decay curve varies widely: 30 to 300 microM (3 to 30 X 10 [-5] M) at 24 hours; 3 to 30 microM (3 to 30 X 10 [-6] M) at 48 hours; &lt;0.3 microM (&lt;3 x 10 [-7] M) at 72 hours. Levels in excess of 5 to 10 microM (5 to 10 x 10 [-6] M) at 24 hours, 1 microM (1 x 10 [-6] M) at 48 hours, and 0.1 micro M (1 x 10 [-7] M) at 72 hours portend greater toxicity, and must be managed by increasing IV hydration and augmenting the dose of <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a>. (See <a class="local">'Management of patients with renal failure and prolonged high plasma methotrexate levels'</a> below.)</p><p></p><p class="bulletIndent1">Because MTX is not a lipophilic compound, it penetrates only slowly across intact cellular barriers such as the vascular endothelium. Third-space fluid collections (eg, ascites, pleural effusions) can accumulate high levels of the drug that slowly leak back into the circulation long after the initial dose. Particularly if renal function is impaired, this can result in prolonged drug elimination and severe delayed toxicity. If possible, these fluid collections should be drained prior to administration of HDMTX.</p><p></p><p class="bulletIndent1">MTX also crosses the blood-brain barrier (BBB). The level of cerebrospinal fluid (CSF) penetration is variable but CSF levels are approximately 3 to 10 percent of plasma concentrations. Thus, high serum levels (typically requiring IV administration of MTX doses ≥1000 mg/m<sup>2</sup>) are required to achieve therapeutic concentrations in the CSF.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Excretion and metabolism</strong> – Almost 90 percent of MTX is excreted unchanged in the urine, the bulk within 12 hours of administration. Although the mechanism of MTX excretion in the human kidney has not been completely elucidated, the finding that MTX clearance exceeds creatinine clearance in several studies suggests that there is active tubular secretion [<a href="#rid32">32,33</a>].</p><p></p><p class="bulletIndent1">Although most MTX is excreted unchanged in the urine, a small amount of the administered dose is excreted unchanged into the bile and undergoes enterohepatic circulation; this is neither clinically relevant nor harmful.</p><p></p><p class="bulletIndent1">Approximately 10 percent of the parent drug is metabolized to 7-hydroxymethotrexate by hepatic aldehyde oxidase. This metabolite is a less potent inhibitor of DHFR but can contribute to renal toxicity due to its lower water solubility [<a href="#rid10">10</a>]. Due to its longer half-life, the serum concentration of 7-hydroxymethotrexate may exceed that of MTX [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1">A less important metabolite, 4-amino-4-deoxy-N10-methylpteroic acid (DAMPA), is produced by bacteria in the intestine as a very small percentage of the administered dose and is not clinically relevant [<a href="#rid34">34</a>].</p><p></p><p class="headingAnchor" id="H204911464"><span class="h3">Causes of delayed clearance</span><span class="headingEndMark"> — </span>Clearance of MTX may be delayed by impaired kidney function, genetic variability, and drug-drug interactions. Delayed clearance increases risk for treatment-related toxicity. (See <a class="local">'Management of patients with renal failure and prolonged high plasma methotrexate levels'</a> below.)</p><p>As examples:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kidney impairment</strong> – Given that most MTX is excreted in the urine, all patients with pre-existing chronic or acute kidney impairment are at risk for delayed clearance and require MTX dose adjustment. (See <a class="local">'Pretreatment assessment'</a> below.)</p><p></p><p class="bulletIndent1">During HDMTX infusion, rapid drug excretion leads to high MTX concentrations in the urine. These concentrations, approaching 10 microM, exceed the solubility of the drug below pH 7 and are thought responsible for intrarenal precipitation of the drug and acute kidney injury. This further interferes with MTX excretion, predisposing patients to potentially severe mucosal toxicity and myelosuppression. In order to prevent intrarenal precipitation, hydration and urinary alkalinization are recommended for HDMTX regimens. (See <a class="local">'Renal toxicity'</a> below and <a class="local">'Hydration and urinary alkalinization'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with Down syndrome</strong> – Trisomy 21 cells (ie, those of patients with Down syndrome) appear to have increased cellular accumulation of MTX because of the presence of extra copies of the reduced folate carrier SLC19A1, which is located on chromosome 21. This increases susceptibility to the systemic toxicity of MTX. As a result, protocols using HDMTX for treatment of diseases such as acute lymphoblastic leukemia in patients with Down syndrome generally recommend a reduced MTX dose [<a href="#rid35">35</a>]. (See  <a class="medical medical_review" href="/z/d/html/4524.html" rel="external">"Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults", section on 'Patients with Down syndrome'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug-drug interactions that impact clearance</strong> – Many drugs inhibit renal excretion of MTX and may increase treatment-related toxicity [<a href="#rid11">11,36</a>]. These include sulfa drugs and <a class="drug drug_general" data-topicid="10024" href="/z/d/drug information/10024.html" rel="external">trimethoprim</a> [<a href="#rid37">37</a>], nonsteroidal anti-inflammatory drugs (NSAIDs) [<a href="#rid38">38</a>], <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a>, penicillin-type drugs [<a href="#rid39">39</a>] <a class="drug drug_general" data-topicid="9812" href="/z/d/drug information/9812.html" rel="external">probenecid</a>, <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>, proton pump inhibitors [<a href="#rid40">40,41</a>], and tyrosine kinase inhibitors such as <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">imatinib</a> and <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">dasatinib</a> [<a href="#rid42">42,43</a>]. Coadministration of these drugs should be avoided, if possible, during HDMTX treatment. (See <a class="local">'Potential drug-drug-interactions'</a> below.)</p><p></p><p class="bulletIndent1">Case reports also suggest that <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">levetiracetam</a> might also alter renal clearance, but the available data are conflicting [<a href="#rid44">44-47</a>]. The United States Prescribing Information for levetiracetam recommends close monitoring of <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> levels when the drugs are coadministered.</p><p></p><p class="headingAnchor" id="H10"><span class="h1">OVERVIEW OF ADVERSE EFFECTS</span><span class="headingEndMark"> — </span>High-dose MTX (HDMTX) can be associated with multiple potential adverse effects, some of which are related to both drug dose and duration of drug exposure; some are idiosyncratic.</p><p class="headingAnchor" id="H11"><span class="h2">Hepatotoxicity</span><span class="headingEndMark"> — </span>MTX has the potential for hepatotoxicity at all doses. The association between MTX and hepatic dysfunction has been studied most extensively in patients receiving chronic oral low-dose MTX for psoriasis and rheumatoid arthritis. Hepatotoxicity can be manifested as a mild transaminitis, but patients are at risk for fibrosis and cirrhosis when the total dose exceeds 1.5 to 2 grams. (See  <a class="medical medical_review" href="/z/d/html/7508.html" rel="external">"Hepatotoxicity associated with chronic low-dose methotrexate for nonmalignant disease"</a>.)</p><p>HDMTX can cause an acute elevation in the serum transaminases from 2- to 20-fold normal levels, even in patients who receive <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> rescue. Acute transaminitis occurs in as many as 60 to 80 percent of patients and typically resolves spontaneously within one to two weeks. If the level of alanine transferase (ALT) has not returned to less than 180 international units/L by the beginning of the next treatment cycle, the next dose should be reduced and/or delayed.</p><p>Rarely, HDMTX causes a temporary elevation in serum bilirubin, which usually normalizes within a few days. Subsequent cycles do not require dose reduction unless the peak serum bilirubin level exceeds 3 mg/dL [<a href="#rid11">11</a>].</p><p>Among patients receiving intravenous (IV) MTX for treatment of cancer, hepatic fibrosis (with a subsequent risk for hepatocellular cancer) is reported only rarely. All cases have been in children receiving MTX for acute lymphoblastic leukemia. (See  <a class="medical medical_review" href="/z/d/html/2837.html" rel="external">"Chemotherapy hepatotoxicity and dose modification in patients with liver disease: Conventional cytotoxic agents", section on 'Methotrexate'</a>.)</p><p>Other hepatotoxic medications and alcohol should be avoided during HDMTX therapy, if at all possible.</p><p class="headingAnchor" id="H12"><span class="h2">Nausea, vomiting, and stomatitis</span><span class="headingEndMark"> — </span>MTX doses above 250 mg/m<sup>2</sup> are considered moderately emetogenic; smaller doses have low or minimal emetogenic potential (≤30 percent risk of emesis). In keeping with guidelines from the American Society of Clinical Oncology (ASCO), patients receiving MTX ≥250 mg/m<sup>2</sup> should be pretreated with a serotonin receptor antagonist and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>, with or without <a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">aprepitant</a> [<a href="#rid48">48</a>]. (See  <a class="medical medical_review" href="/z/d/html/1150.html" rel="external">"Pathophysiology and prediction of chemotherapy-induced nausea and vomiting"</a> and  <a class="medical medical_review" href="/z/d/html/1151.html" rel="external">"Prevention of chemotherapy-induced nausea and vomiting in adults"</a>.)</p><p>Mucositis is typically avoided in patients who undergo successful <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> rescue. Mucositis may be severe after HDMTX if leucovorin rescue is delayed or in the setting of prolonged elevated serum levels. (See <a class="local">'Rationale for leucovorin rescue'</a> above.)</p><p class="headingAnchor" id="H13"><span class="h2">Renal toxicity</span><span class="headingEndMark"> — </span>At low doses, MTX is not nephrotoxic. However, HDMTX can affect the kidneys in two different ways [<a href="#rid49">49</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The main cause is that MTX can precipitate in the tubules and directly induce tubular injury. The risk is increased in the presence of acidic urine (since MTX and its two major metabolites are poorly soluble at an acid pH), with volume depletion (which decreases urine flow rate and increases the concentration of MTX in tubular fluid) and when high plasma MTX concentrations are sustained.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>MTX also causes a transient decline in glomerular filtration rate (GFR) after each dose, with complete recovery within six to eight hours. The mechanism responsible for this functional renal impairment involves afferent arteriolar constriction or mesangial cell constriction. The effect can be exacerbated when additional nephrotoxic drugs (eg, <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>) are administered.</p><p></p><p>MTX-induced acute renal failure is typically nonoliguric and is reversible in almost all cases. Plasma creatinine levels usually peak within the first week and return toward baseline levels within one to three weeks. (See  <a class="medical medical_review" href="/z/d/html/7229.html" rel="external">"Crystal-induced acute kidney injury", section on 'Methotrexate'</a>.)</p><p>The major risk with MTX-induced renal dysfunction is that MTX clearance is severely compromised, resulting in delayed excretion of the drug, higher than expected plasma concentrations, and increased systemic toxicity.</p><p>The likelihood of MTX-induced renal dysfunction in patients receiving HDMTX can be minimized (but not eliminated) by hydration both to maintain a high urine flow and to lower the concentration of MTX in the tubular fluid and by alkalinization of the urine to a pH above 7.0. Raising the urine pH from 5.0 to 7.0 increases the solubility of MTX 10-fold [<a href="#rid49">49,50</a>]. (See <a class="local">'Hydration and urinary alkalinization'</a> below.)</p><p>Despite these measures, the risk of renal failure after HDMTX is still approximately 2 percent. In a review of the literature and clinical trial reports of children treated with HDMTX for osteosarcoma after 1980, a time during which hydration and alkalinization were administered routinely, the incidence of renal dysfunction was 1.8 percent and the mortality among patients who developed renal dysfunction was 4.4 percent [<a href="#rid51">51</a>]. The incidence may be higher in adults, especially those treated for hematologic malignancies [<a href="#rid52">52</a>].</p><p>If the patient develops HDMTX-related nephrotoxicity during treatment, the serum creatinine should be serially monitored, and subsequent doses held until the serum creatinine has returned to baseline. Management of patients with renal failure and prolonged excretion of MTX is discussed below. (See <a class="local">'Management of patients with renal failure and prolonged high plasma methotrexate levels'</a> below.)</p><p class="headingAnchor" id="H14"><span class="h2">Hematologic toxicity</span><span class="headingEndMark"> — </span>In contrast to the situation with low-dose oral MTX, in which hematologic toxicity can be the major dose-limiting side effect, there is usually little evidence of treatment-related myelosuppression following HDMTX with <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> rescue. Myelosuppression may become evident if rescue is delayed or in the setting of prolonged elevated serum levels. (See <a class="local">'Rationale for leucovorin rescue'</a> above and  <a class="medical medical_review" href="/z/d/html/7509.html" rel="external">"Major side effects of low-dose methotrexate"</a>.)</p><p class="headingAnchor" id="H15"><span class="h2">Pulmonary toxicity</span><span class="headingEndMark"> — </span>The pattern of lung toxicity most frequently seen in patients treated with MTX is a hypersensitivity pneumonitis. Although this most often occurs after long-term oral therapy, pulmonary toxicity can occur following HDMTX. In contrast to bone marrow and GI epithelial toxicity, the repletion of folate stores does <strong>not</strong> reduce the risk for MTX pulmonary toxicity, suggesting that it results from an idiosyncratic mechanism unrelated to folate antagonism.</p><p>The majority of patients who develop pulmonary toxicity do so within the first year of therapy, although cases are reported as early as 12 days and as late as 18 years after drug initiation. The presentation may be acute, subacute, or chronic. Subacute presentations are most common, manifesting with dyspnea, nonproductive cough, fever, crackles on auscultation of the lungs, hypoxemia, and peripheral blood eosinophilia in up to one-half of affected patients. Widespread interstitial lung opacities are the earliest radiographic findings and may progress rapidly to patchy acinar consolidation.</p><p>For patients who develop pulmonary findings during treatment, the drug should be discontinued and an infectious etiology for the pulmonary findings excluded. If symptoms, radiographic findings, or physiologic abnormalities persist despite drug discontinuation or if the patient is severely ill, glucocorticoids are indicated, although they have varying degrees of success. This topic is discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4372.html" rel="external">"Methotrexate-induced lung injury"</a>.)</p><p class="headingAnchor" id="H16"><span class="h2">Neurologic toxicity</span><span class="headingEndMark"> — </span>Acute or subacute encephalopathy is the most important neurotoxicity of HDMTX. This complication is characterized by somnolence, confusion, and seizures within 24 hours of treatment. Symptoms usually resolve spontaneously without sequelae, and retreatment is often possible. Neurologic toxicity of MTX is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/2836.html" rel="external">"Overview of neurologic complications of conventional non-platinum cancer chemotherapy", section on 'Methotrexate'</a>.)</p><p class="headingAnchor" id="H17"><span class="h2">Dermatologic toxicity</span><span class="headingEndMark"> — </span>A variety of dermatologic side effects are described. Approximately 14 to 15 percent of patients develop a nonspecific morbilliform drug rash, which is usually erythematous, macular, pruritic, and often confined to the neck and trunk [<a href="#rid53">53,54</a>]. In severe cases, it can progress to bullous formation or desquamation. MTX can also cause photoreactivation and photoenhancement as well as skin hyperpigmentation, and photoreactivation may be magnified by concomitant use of other drugs such as <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a>. (See  <a class="medical medical_review" href="/z/d/html/2090.html" rel="external">"Cutaneous adverse effects of conventional chemotherapy agents"</a>.)</p><p>Alopecia is occasionally encountered but is usually not complete. (See  <a class="medical medical_review" href="/z/d/html/1156.html" rel="external">"Alopecia related to systemic cancer therapy"</a>.)</p><p class="headingAnchor" id="H18"><span class="h2">Hypersensitivity</span><span class="headingEndMark"> — </span>True hypersensitivity reactions to MTX are rare [<a href="#rid55">55</a>]. Successful rechallenge has been reported using a desensitization protocol. (See  <a class="medical medical_review" href="/z/d/html/2835.html" rel="external">"Infusion reactions to systemic chemotherapy"</a>.)</p><p class="headingAnchor" id="H19"><span class="h1">ONCOLOGIC INDICATIONS FOR HIGH-DOSE METHOTREXATE</span><span class="headingEndMark"> — </span>High-dose MTX (HDMTX) is a component of modern treatment protocols for certain leukemias, high-risk peripheral as well as central nervous system lymphomas, osteosarcoma, and is an alternative to intrathecal (IT) MTX for treatment of leptomeningeal metastases.</p><p>The specific dose and schedule of HDMTX vary according to the disease and the specific regimen and are discussed in depth under the specific disorders. The following sections provide a brief overview as to how HDMTX is incorporated into the treatment of these conditions.</p><p class="headingAnchor" id="H20"><span class="h2">Leukemia and lymphoma</span><span class="headingEndMark"> — </span>Leukemic and lymphomatous meningitis are fairly common at presentation; the incidence is between 3 and 5 percent. Furthermore, central nervous system (CNS) relapse develops in 5 to 10 percent of patients.</p><p>For non-Hodgkin lymphomas, the risk of CNS disease is greatest in patients with highly aggressive lymphomas (eg, Burkitt's lymphoma) and in patients with aggressive lymphomas who have advanced disease. Specific risk factors for CNS lymphoma, which may involve the brain parenchyma and/or the leptomeninges, include a high International Prognostic Index (IPI), multiple extranodal sites, renal or adrenal disease, disease involving the testes and possibly the bone marrow (this is quite controversial), and the presence of human immunodeficiency virus (HIV) disease. (See  <a class="medical medical_review" href="/z/d/html/4720.html" rel="external">"Secondary central nervous system lymphoma: Clinical features and diagnosis"</a>.)</p><p class="headingAnchor" id="H21"><span class="h3">Acute lymphoblastic leukemia</span><span class="headingEndMark"> — </span>At least in part due to the gradual shift away from radiation therapy for CNS prophylaxis, many if not all protocols for treating acute lymphoblastic leukemia (ALL) incorporate HDMTX to provide systemic and CNS cytotoxic effects.</p><p>There is no "standard" method of administering HDMTX for ALL. The dose, infusion duration, and timing of <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> rescue vary markedly among various protocols. A major area of controversy is whether higher peak plasma MTX levels (as can be achieved with higher doses given over a shorter period of time) or greater AUC (area under the concentration x time curve, achieved with longer infusion times and lower doses) correlate best with clinical outcomes [<a href="#rid56">56,57</a>].</p><p>As noted above, patients with trisomy 21 (Down syndrome) are at risk for excessive toxicity from HDMTX due to presence of extra copies of the folate transporter SLC191A, and doses should be reduced in these patients. (See <a class="local">'Causes of delayed clearance'</a> above.)</p><p>Specific protocols that incorporate HDMTX into treatment are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4524.html" rel="external">"Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6245.html" rel="external">"Treatment of acute lymphoblastic leukemia/lymphoma in children and adolescents"</a>.)</p><p class="headingAnchor" id="H22"><span class="h3">Primary central nervous system lymphoma</span><span class="headingEndMark"> — </span>HDMTX is the mainstay of most treatment regimens for primary and secondary CNS lymphoma. (See  <a class="medical medical_review" href="/z/d/html/4751.html" rel="external">"HIV-related lymphomas: Primary central nervous system lymphoma", section on 'High-dose methotrexate'</a> and  <a class="medical medical_review" href="/z/d/html/89417.html" rel="external">"Secondary central nervous system lymphoma: Treatment and prognosis", section on 'Methotrexate-based induction regimens'</a>.)</p><p class="headingAnchor" id="H23"><span class="h3">Systemic non-Hodgkin lymphoma</span><span class="headingEndMark"> — </span>HDMTX is an integral component of therapeutic regimens for the highly aggressive Burkitt lymphomas to treat and/or prevent CNS involvement. (See  <a class="medical medical_review" href="/z/d/html/4734.html" rel="external">"Treatment of Burkitt leukemia/lymphoma in adults"</a>.)</p><p>HDMTX (or intrathecal MTX) is also employed for CNS prophylaxis in patients with certain diffuse large B cell lymphomas that are associated with a high risk of CNS relapse, as well as in patients with known CNS involvement, although its value is uncertain. (See  <a class="medical medical_review" href="/z/d/html/4729.html" rel="external">"Initial treatment of advanced stage diffuse large B cell lymphoma", section on 'CNS management'</a>.)</p><p class="headingAnchor" id="H24"><span class="h2">Osteosarcoma</span><span class="headingEndMark"> — </span>With the recognition that almost all osteosarcomas have micrometastatic disease at diagnosis even if they appear localized, systemic chemotherapy has become an integral part of curative therapy for this disease. The majority of pediatric protocols include HDMTX at doses range from 8 to 12 g/m<sup>2</sup>. Many studies indicate a correlation between peak MTX plasma levels, tumor response, and long-term outcome. (See  <a class="medical medical_review" href="/z/d/html/7723.html" rel="external">"Chemotherapy and radiation therapy in the management of osteosarcoma", section on 'Role of high-dose methotrexate'</a>.)</p><p>The role of adjuvant HDMTX is more controversial in adults with osteosarcoma because randomized studies have failed to show an advantage for higher as compared with intermediate doses of MTX or for HDMTX plus <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a> and <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> versus doxorubicin/cisplatin alone. (See  <a class="medical medical_review" href="/z/d/html/7723.html" rel="external">"Chemotherapy and radiation therapy in the management of osteosarcoma", section on 'Chemotherapy in adults'</a>.)</p><p>HDMTX is also an important agent for metastatic osteosarcoma; response rates, when used as a single agent in the metastatic setting, are in the range of 30 to 40 percent [<a href="#rid58">58</a>]. (See  <a class="medical medical_review" href="/z/d/html/7723.html" rel="external">"Chemotherapy and radiation therapy in the management of osteosarcoma", section on 'Patients with metastatic disease at diagnosis'</a>.)</p><p class="headingAnchor" id="H25"><span class="h2">Leptomeningeal metastases</span><span class="headingEndMark"> — </span>MTX is the chemotherapeutic agent most commonly used for IT chemotherapy in patients with leptomeningeal metastases. Furthermore, systemic administration of HDMTX is the most widely used alternative to IT chemotherapy in this setting and achieves higher CSF concentrations than does IT administration. The level of cerebrospinal fluid (CSF) penetration is variable but CSF levels are approximately 3 to 10 percent of plasma concentrations. (See  <a class="medical medical_review" href="/z/d/html/5184.html" rel="external">"Treatment of leptomeningeal disease from solid tumors"</a>.)</p><p class="headingAnchor" id="H26"><span class="h1">PRACTICAL TIPS FOR MANAGING HIGH-DOSE METHOTREXATE</span><span class="headingEndMark"> — </span>As noted above, the specific details of MTX dose, infusion duration, and <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> rescue are generally disease- and protocol-specific. However, there are some general aspects of high-dose MTX (HDMTX) administration and posttreatment management that are common to all regimens.</p><p class="headingAnchor" id="H27"><span class="h2">Pretreatment assessment</span><span class="headingEndMark"> — </span>HDMTX requires central venous access or excellent large-caliber peripheral venous access and at least two to three days of inpatient care. Although outpatient administration of HDMTX is feasible [<a href="#rid59">59</a>], it requires a highly motivated and reliable patient, daily outpatient visits, and rigorous attention to hydration status, urinary output, and urine pH. The development of nausea or diarrhea leading to volume depletion renders outpatient management unsuitable.</p><p class="headingAnchor" id="H1239901812"><span class="h3">Exclude a third-space fluid collection</span><span class="headingEndMark"> — </span>As noted above, patients with ascites or pleural effusions can accumulate MTX in these "third spaces," which can lead to delayed elimination as the MTX slowly leaches out of the fluid collection, particularly if renal function is impaired. Clearance may also be delayed in those with anasarca, in the absence of obvious third-space fluid collections.</p><p>If present, third-space fluid collections should be treated and/or drained prior to the first dose of MTX. If this is not feasible, the possibility that plasma MTX levels may remain elevated for longer than 72 hours should be anticipated. (See <a class="local">'Pharmacokinetics, metabolism, and excretion'</a> above.)</p><p class="headingAnchor" id="H28"><span class="h3">Kidney function</span><span class="headingEndMark"> — </span>Because MTX is cleared predominantly by the kidney, assessment of renal function is necessary prior to each dose of HDMTX. If the serum creatinine is initially high, we would hydrate the patient and recheck the value. If the serum creatinine is still elevated, dose reduction may be warranted. There is no consensus as to which of the several dose reduction schema are optimal (for children and adults), and institutional practice varies. In practice, particularly if treatment is being administered with curative intent, dose reductions are rarely performed for baseline altered renal function. On the other hand, if the patient develops HDMTX-related nephrotoxicity during treatment, serum creatinine should be serially monitored and subsequent dosing held until the serum creatinine has returned to baseline. (See <a class="local">'Renal toxicity'</a> above.)</p><p>There are no universally agreed upon guidelines for dose reduction based on baseline renal function; the US Food and Drug Administration (FDA)-approved manufacturer's product labeling does not include recommendations. The following dose reduction schema have been suggested by expert groups:</p><p>Aronoff recommends the following dose modifications for adults [<a href="#rid60">60</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Creatinine clearance (CrCl) 10 to 50 mL/min – Reduce dose to 50 percent of usual dose</p><p class="bulletIndent1"><span class="glyph">●</span>CrCl &lt;10 mL/min – Avoid use of MTX</p><p class="bulletIndent1"><span class="glyph">●</span>Hemodialysis/continuous renal replacement therapy – Administer 50 percent of the dose (others suggest that only 25 percent of the dose be administered after hemodialysis [<a href="#rid61">61</a>]) </p><p></p><p>Kintzel provided slightly different recommendations [<a href="#rid62">62</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>CrCl 46 to 60 mL/min – Reduce dose to 65 percent of usual dose</p><p class="bulletIndent1"><span class="glyph">●</span>CrCl 31 to 45 mL/min – Reduce dose to 50 percent of usual dose </p><p class="bulletIndent1"><span class="glyph">●</span>CrCl &lt;30 mL/min – Avoid use of MTX</p><p></p><p>Others suggest that the MTX dose be reduced by the percentage reduction of the measured CrCl below 100 mL/min (eg, for a CrCl 60 mL/min, the dose would be reduced by 40 percent) [<a href="#rid63">63</a>].</p><p>One published trial of adults receiving HDMTX for acute leukemia recommended that the HDMTX dose be based on serum creatinine on the day of treatment [<a href="#rid64">64</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Serum creatinine &lt;1.5 mg/dL – 100 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Serum creatinine 1.5 to 2.0 mg/dL – Reduce dose to 75 percent of usual dose</p><p class="bulletIndent1"><span class="glyph">●</span>Serum creatinine &gt;2.0 mg/dL – Reduce dose to 50 percent of usual dose</p><p></p><p>There is no consensus as to which one of these dose reduction schema are optimal (for children and adults), and institutional practice is variable. In practice, particularly if treatment is being administered with curative intent, dose reductions are rarely performed for baseline altered renal function. On the other hand, if the patient develops HDMTX-related nephrotoxicity during treatment, the serum creatinine should be serially monitored, and subsequent dosing held until the serum creatinine has returned to baseline. (See <a class="local">'Renal toxicity'</a> above.)</p><p>There is also no consensus on how best to periodically assess CrCl during treatment regimens that include drugs that are dependent on renal elimination. Some protocols require 24-hour urine collection and measurement of CrCl as an obligatory part of each pre-dose evaluation. However, it is not clear that 24-hour urine collection is necessary or sufficient for all patients [<a href="#rid65">65</a>]. Some studies suggest greater accuracy for estimating CrCl (and therefore, GFR) using the Wright formula [<a href="#rid66">66</a>], the Cockcroft-Gault formula [<a href="#rid63">63</a>], or by use of the simplified modification of diet in renal disease (MDRD) equation (<a class="calc calc_professional" href="/z/d/html/13496.html" rel="external">calculator 1</a> and <a class="calc calc_professional" href="/z/d/html/15635.html" rel="external">calculator 2</a>) [<a href="#rid65">65</a>].</p><p>However, any estimation of GFR based on either a 24-hour urine collection or calculated from the serum creatinine is imprecise, and a patient may be incorrectly labeled as having a low GFR. This must be considered when weighing the potential risk of increased drug toxicity in a patient with reduced GFR against the potential benefit to be derived from therapy. These issues are addressed in detail elsewhere (see  <a class="medical medical_review" href="/z/d/html/2834.html" rel="external">"Nephrotoxicity of chemotherapy and other cytotoxic agents"</a>). The K/DOQI clinical practice guidelines for CKD, as well as other K/DOQI guidelines, can be accessed through the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.kidney.org%2Fprofessionals%2Fguidelines&amp;token=mwx%2FWFqfIsxpjED21OsijeC6nVb9OOdf2ctFKSDhUkeo7woDHDqqTAFuB14mPyNw1FjMB29uSsN6BBA179a0fw%3D%3D&amp;TOPIC_ID=1155" target="_blank">National Kidney Foundation's</a> website.</p><p class="headingAnchor" id="H1416591943"><span class="h4">Issues specific to older patients</span><span class="headingEndMark"> — </span>There is potential for <strong>over</strong>estimation of the CrCl for older adult patients, as well as others with cachexia, if they have abnormally low serum creatinine levels. Consensus-based guidelines from the National Comprehensive Cancer Network propose using minimal value of 0.7 for the serum creatinine for calculations [<a href="#rid67">67</a>].</p><p>While many studies have shown that older adults are able to tolerate and derive benefit from high dose <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> [<a href="#rid68">68,69</a>], close adherence to dose reductions as determined by the calculated CrCl before each cycle is needed as some studies have shown higher levels of acute kidney injury in older patients [<a href="#rid70">70</a>] as well as those with diabetes mellitus [<a href="#rid71">71</a>].</p><p class="headingAnchor" id="H1350698"><span class="h3">Baseline hepatic impairment</span><span class="headingEndMark"> — </span>Dose adjustment is not provided in the manufacturer's labeling. The following dose reductions have been suggested by one expert group [<a href="#rid72">72</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Serum bilirubin 3.1 to 5 mg/dL or transaminases &gt;3 times the upper limit of normal – Administer 75 percent of the usual dose</p><p class="bulletIndent1"><span class="glyph">●</span>Serum bilirubin &gt;5 mg/dL – Avoid use </p><p></p><p class="headingAnchor" id="H1350729"><span class="h3">Obesity</span><span class="headingEndMark"> — </span>ASCO guidelines for appropriate chemotherapy dosing in persons with obesity who have cancer recommend use of the patient's actual body weight for calculation of body surface area, particularly when the intent of therapy is curative [<a href="#rid73">73</a>]. (See  <a class="medical medical_review" href="/z/d/html/83810.html" rel="external">"Dosing of anticancer agents in adults", section on 'Dosing for overweight/obese patients'</a>.)</p><p class="headingAnchor" id="H5670353"><span class="h3">Potential drug-drug-interactions</span><span class="headingEndMark"> — </span>As noted above, many drugs, including nonsteroidal anti-inflammatory drugs (NSAIDs), <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a>, sulfa drugs, <a class="drug drug_general" data-topicid="10024" href="/z/d/drug information/10024.html" rel="external">trimethoprim</a>, penicillin-type drugs, <a class="drug drug_general" data-topicid="9812" href="/z/d/drug information/9812.html" rel="external">probenecid</a>, <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>, tyrosine kinase inhibitors (including <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">imatinib</a> and <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">dasatinib</a>), and proton pump inhibitors, inhibit excretion of MTX. Their use should be avoided, if possible, during HDMTX treatment. (See <a class="local">'Causes of delayed clearance'</a> above.)</p><p>Case reports also suggest that <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">levetiracetam</a> might also alter renal clearance, but the available data are conflicting. The United States Prescribing Information for levetiracetam recommends close monitoring of <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> levels in patients receiving levetiracetam.</p><p class="headingAnchor" id="H29"><span class="h2">Prevention and management of high-dose methotrexate toxicity</span><span class="headingEndMark"> — </span>The guiding principles for prevention of HDMTX toxicity, namely maintaining urine output, urinary alkalinization, monitoring serum creatinine, electrolytes, and plasma MTX concentrations, and pharmacokinetically guided <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> rescue, are also the cornerstones of management for patients who develop early signs of renal dysfunction and delayed MTX elimination.</p><p class="headingAnchor" id="H30"><span class="h3">Hydration and urinary alkalinization</span><span class="headingEndMark"> — </span>Maintaining adequate hydration and urine output is essential for rapid clearance of MTX. Most protocols recommend at least 2.5 to 3.5 liters/m<sup>2</sup> of intravenous (IV) fluid hydration per day, starting 4 to 12 hours prior to the initiation of the MTX infusion.</p><p>The pH of the urine should be measured at baseline. As noted above, MTX precipitates in acid urine; maintaining the urine pH 7.0 or higher increases MTX solubility, prevents drug precipitation in renal tubules, and drastically decreases the chance of renal damage. In clinical practice, it is customary to begin the MTX infusion only after the urine pH is ≥7.0 and to maintain it in this range until plasma MTX levels have declined to less than 0.1 microM.</p><p>Urinary alkalinization is most easily accomplished by adding ampules of <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">sodium bicarbonate</a> to each liter of IV fluid hydration. This accomplishes both fluid hydration and urinary alkalinization.</p><p>A typical choice is IV D5W with 100 to 150 mEq of <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">sodium bicarbonate</a> per liter, administered by continuous infusion at 125 to 150 mL/hour. A cation concentration of 80.5 mEq/L is roughly equivalent to one-half normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>. The amount of bicarbonate in each liter and the IV fluid composition can then be modified according to the urine pH and serum sodium. If only 50 mEq of sodium bicarbonate is added to each liter of IV fluid, clinicians should be aware that the resultant fluid will be hypotonic if D5W is used. (See  <a class="medical medical_review" href="/z/d/html/2296.html" rel="external">"Maintenance and replacement fluid therapy in adults", section on 'Replacement fluid therapy'</a>.)</p><p>Alternatively, <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">sodium bicarbonate</a> dosing can be accomplished intermittently either by the IV or oral route:</p><p class="bulletIndent1"><span class="glyph">●</span>50 mL of D5W containing <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">sodium bicarbonate</a> 1 mEq/kg can be infused IV over 30 minutes every four or six hours.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Oral <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">sodium bicarbonate</a> can also be given although the dose is variable. At our institution, we start with 3250 mg (five tablets) every six hours, and escalate to five tablets every two to four hours as needed; once the urine pH is ≥7, the 24 hour daily dose can usually be divided into four doses, every six hours. An alternative oral protocol is available [<a href="#rid74">74</a>].</p><p></p><p>As with continuous administration of IV bicarbonate-containing fluid, the urine pH should be ≥7.0 before the MTX infusion is begun, and urine pH must be monitored closely until serum MTX levels are below 0.1 microM to ensure that the urine is still adequately alkalinized. (See <a class="local">'Laboratory monitoring during treatment'</a> below.)</p><p>Frequent measurement of urine pH and urine output (recommended at least every two to four hours) will ensure that the urine remains alkalinized and diuresis is appropriate to prevent nephrotoxicity [<a href="#rid75">75,76</a>]. Oral <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">sodium bicarbonate</a> can be added if the urine pH decrease to &lt;7.</p><p class="headingAnchor" id="H1983184444"><span class="h4">Interference with urinary alkalinization</span><span class="headingEndMark"> — </span>Few foods or beverages are known to be associated with delayed MTX clearance or toxicity. However, at least some evidence suggests that intake of cola beverages during MTX treatment may lead to urinary acidification (due to the phosphoric acid content) and delayed MTX clearance [<a href="#rid77">77</a>].</p><p>Although some protocols restrict dietary intake of colas and other acidic foods (eg, orange juice, tomato products) during HDMTX treatment until levels are below 0.1 microM. Others recommend avoidance of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> and other NSAIDs and vitamins (particularly <a class="drug drug_general" data-topicid="9776" href="/z/d/drug information/9776.html" rel="external">vitamin C</a>) until plasma MTX levels are less than 0.1 microM. In our view, as long as urine pH can be maintained above 7.0, dietary and medication restriction is unnecessary.</p><p class="headingAnchor" id="H31"><span class="h3">Leucovorin administration</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">Leucovorin</a> rescue should be started within 24 to 36 hours of the start of the MTX infusion. Most American patients receive a racemic mixture of d,l-leucovorin (leucovorin or leucovorin calcium). However, the l-isomer is the biologically active moiety (ie, has the capacity to rescue cells from MTX toxicity [<a href="#rid75">75</a>]), and an IV preparation of l-leucovorin is now commercially available in the United States (<a class="drug drug_general" data-topicid="10324" href="/z/d/drug information/10324.html" rel="external">LEVOleucovorin</a>, Fusilev, Khapzory). It is dosed at one-half that of d,l leucovorin.</p><p>A variety of dosing schedules have been published for <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a>, but most administer 10 mg/m<sup>2</sup> IV or 15 mg/m<sup>2</sup> of leucovorin calcium orally (or 5 mg/m<sup>2</sup> of <a class="drug drug_general" data-topicid="10324" href="/z/d/drug information/10324.html" rel="external">levoleucovorin</a> IV) every six hours until plasma MTX levels are less than 0.05 to 0.1 microM [<a href="#rid78">78</a>].</p><p>The size and number of <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> doses do not appear to be critical in patients who have <strong>normal</strong> MTX clearance [<a href="#rid7">7</a>]. Even doses of 10 to 15 mg/m<sup>2</sup> are often in excess of those required to achieve rescue in such patients [<a href="#rid79">79</a>]. By contrast, higher concentrations of leucovorin are needed if rapid elimination of MTX is compromised by renal insufficiency. Management of leucovorin dosing in patients with delayed elimination and prolonged elevated plasma MTX levels is discussed below. (See <a class="local">'Increased dose and frequency of leucovorin'</a> below.)</p><p class="headingAnchor" id="H1067627855"><span class="h4">Oral versus intravenous</span><span class="headingEndMark"> — </span>Orally administered <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> can successfully reverse MTX toxicity. The inactive d-isomer has a longer plasma half-life than the active l-isomer [<a href="#rid80">80</a>], and at least in theory, repeated parenteral administration of the d,l racemic mixture may result in selective accumulation of the inactive d-isomer, which could, at least in theory, compete with the active isomer for cellular uptake, compromising efficacy. Since the active l-isomer is preferentially absorbed from the intestinal tract, oral rather than IV administration of leucovorin calcium may be preferred in this setting as long as the dose is 25 mg or less (oral bioavailability is reduced at doses 40 mg and above [<a href="#rid81">81,82</a>]). <a class="drug drug_general" data-topicid="10324" href="/z/d/drug information/10324.html" rel="external">LEVOleucovorin</a> is not available as an oral preparation.</p><p>For doses higher than 25 mg, oral bioavailability of the active l-isomer is significantly decreased, and IV administration of either the d,l racemic mixture or <a class="drug drug_general" data-topicid="10324" href="/z/d/drug information/10324.html" rel="external">levoleucovorin</a> is preferred.</p><p class="headingAnchor" id="H32"><span class="h3">Laboratory monitoring during treatment</span><span class="headingEndMark"> — </span>Laboratory monitoring during treatment with HDMTX is mandatory. Serum creatinine and electrolytes as well as plasma MTX levels should be followed daily. A rise in the serum creatinine above normal values indicates acute renal dysfunction and the potential for delayed MTX elimination, which may prompt an increase in the dose and duration of <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> rescue, and consideration for use of <a class="drug drug_general" data-topicid="9048" href="/z/d/drug information/9048.html" rel="external">glucarpidase</a>. (See <a class="local">'Increased dose and frequency of leucovorin'</a> below and <a class="local">'Glucarpidase (carboxypeptidase G2)'</a> below.)</p><p>Early studies conducted in the 1970s revealed that the following drug levels after MTX infusion indicated a high risk for bone marrow and gastrointestinal mucosal toxicity [<a href="#rid79">79,83-86</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Levels above 5 to 10 microM at 24 hours</p><p class="bulletIndent1"><span class="glyph">●</span>Levels above 0.9 to 1 microM at 48 hours</p><p class="bulletIndent1"><span class="glyph">●</span>Levels above 0.1 microM at 72 hours</p><p></p><p>These studies also showed that the risk of MTX-associated toxicity is minimal in the absence of elevated MTX concentrations, and that in most circumstances, the development of MTX-associated toxicities can be ameliorated or prevented when patients with MTX drug levels in this range at these time points receive pharmacokinetically guided doses of <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> rescue.</p><p>As a result, it is mandatory that all patients receiving HDMTX have plasma MTX levels determined after dosing. Monitoring of serum creatinine alone is inadequate since there are large interindividual variations in MTX clearance and a poor correlation between serum creatinine and MTX clearance [<a href="#rid83">83,87,88</a>].</p><p>It is customary to assay plasma MTX levels at 24, 48, and 72 hours after the start of the MTX infusion; more frequent monitoring may be needed. Consensus-based recommendations for the timing of MTX levels following HDMTX are available [<a href="#rid89">89</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>For infusions over six hours or less <a class="drug drug_general" data-topicid="9048" href="/z/d/drug information/9048.html" rel="external">glucarpidase</a> may be indicated if the 24-hour concentration is above 50 microM, the 36-hour concentration is above 30 microM, the 42-hour concentration is above 10 microM, or the 48-hour concentration is above 5 microM and the serum creatinine is elevated relative to baseline measurement (indicative of HDMTX-induced acute kidney injury).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For 24- to 42-hour infusional regimens, the initial MTX measurement should be at 24 hours; if the level is &gt;120 microM at that time, or the creatinine has increased ≥50 percent over baseline, this warrants additional monitoring at 36, 42, and 48 hours. If the 36-hour MTX concentration is above 30 microM, the 42-hour MTX concentration is above 10 microM, or the 48-hour concentration is above 5 microM and the serum creatinine is elevated relative to baseline measurement (indicative of HDMTX-induced acute kidney injury), <a class="drug drug_general" data-topicid="9048" href="/z/d/drug information/9048.html" rel="external">glucarpidase</a> rescue may be indicated. (See <a class="local">'Glucarpidase (carboxypeptidase G2)'</a> below.)</p><p></p><p>Most sites monitor plasma MTX concentrations until they are &lt;0.1 to 0.2 microM.</p><p><a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">Leucovorin</a> doses should be adjusted based on the MTX drug levels, and hydration/alkalinization is continued or increased provided that adequate urine output can be maintained [<a href="#rid90">90</a>]. (See <a class="local">'Management of patients with renal failure and prolonged high plasma methotrexate levels'</a> below.)</p><p class="headingAnchor" id="H33"><span class="h2">Management of patients with renal failure and prolonged high plasma methotrexate levels</span><span class="headingEndMark"> — </span>Delayed renal elimination can result in elevated plasma MTX levels for as long as two to three weeks, which increases systemic toxicity. Risk factors contributing to renal failure and delayed clearance of MTX include urine pH &lt;7, less than 3 L/m<sup>2</sup> of IV fluid hydration per 24 hours, high body mass index, use of concomitant medications with nephrotoxic potential or known interference with MTX elimination (eg, salicylates, nonsteroidal anti-inflammatory drugs, beta-lactam antibiotics, sulfonamides, aminoglycosides, and proton pump inhibitors), pre-existing hepatic or renal dysfunction, and the presence of third-space fluid collections [<a href="#rid91">91</a>].</p><p>In this setting, the risk of treatment-related toxicity may be diminished by the following maneuvers:</p><p class="headingAnchor" id="H34"><span class="h3">Augmenting urine output</span><span class="headingEndMark"> — </span>Since the rate of MTX elimination is dependent on urine output, hydration and urinary alkalinization should be continued or increased, provided that adequate urine output can be maintained.</p><p class="headingAnchor" id="H35"><span class="h3">Increased dose and frequency of leucovorin</span><span class="headingEndMark"> — </span>Because the reversal of MTX action by <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> is competitive, proportionately higher leucovorin concentrations are required to achieve rescue in the presence of high MTX levels [<a href="#rid7">7,79,92</a>]. In one study, five of 12 patients with 48-hour MTX levels &gt;0.9 microM who were treated with leucovorin doses 6 to 30 mg/m<sup>2</sup> developed toxicity, compared with none of those who received 50 to 150 mg/m<sup>2</sup> every six hours [<a href="#rid79">79</a>]. Others have observed occasional patients with delayed MTX clearance and sustained plasma levels &gt;10 microM in whom toxicity seemed to improve when large doses of leucovorin were given [<a href="#rid93">93</a>].</p><p>Specific dose modification schema for <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> varies broadly among protocols and institutions. The following table shows guidelines for dose and schedule adjustment for leucovorin (the d,l racemic mixture) recommended by the manufacturer  (<a class="graphic graphic_table graphicRef51155" href="/z/d/graphic/51155.html" rel="external">table 3</a>). Guidelines for dose and schedule adjustments for <a class="drug drug_general" data-topicid="10324" href="/z/d/drug information/10324.html" rel="external">LEVOleucovorin</a> in patients with delayed MTX clearance recommended by the manufacturer are outlined in the table  (<a class="graphic graphic_table graphicRef64297" href="/z/d/graphic/64297.html" rel="external">table 4</a>). Higher-dose leucovorin dosing nomograms have been developed [<a href="#rid10">10,94</a>] and are in use in some institutions [<a href="#rid49">49,95</a>]. However, there is no evidence to suggest that these higher-dose regimens are more effective than the guidelines provided in the United States prescribing information.</p><p>The dosing interval for <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> has been derived empirically; the half-life of its primary active metabolite is approximately four to six hours [<a href="#rid81">81</a>]. The benefit of dosing every three to four as compared with every six hours has not been proven, although mean plasma levels are two to three times higher with every three hour administration [<a href="#rid96">96</a>]. The duration of leucovorin rescue is often more critical than the dose or dosing interval, since elevated plasma levels may persist for several days [<a href="#rid7">7</a>].</p><p>As noted previously, <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> selectively rescues normal but not malignant cells from the effects of MTX (see <a class="local">'Rationale for leucovorin rescue'</a> above). It is not clear that there is any dose of leucovorin that is sufficiently high to interfere with antitumor efficacy. Although leucovorin "overrescue" has rarely been described in children receiving HDMTX for childhood ALL or osteosarcoma [<a href="#rid97">97,98</a>], its clinical relevance is debated [<a href="#rid99">99</a>].</p><p class="headingAnchor" id="H36"><span class="h2">Alternative rescue techniques for patients with renal failure</span><span class="headingEndMark"> — </span>Whether higher doses of <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> alone are sufficient in the setting of renal failure and severe MTX intoxication is debated. In vitro data suggest that rescue of the toxic effects of MTX by leucovorin is not observed when cells are exposed to MTX concentrations ≥100 microM [<a href="#rid100">100</a>]. Clinical data are scarce. In a retrospective review of 13 patients with MTX levels &gt;100 microM at 24 hours and &gt;10 microM at 48 hours after HDMTX, all patients recovered with the use of high-dose leucovorin alone in conjunction with hydration and alkalinization, but short-term morbidity (myelosuppression, mucositis, diarrhea) was prominent [<a href="#rid101">101</a>]. Thus, these data support the view that leucovorin alone is not optimal.</p><p>Alternative rescue techniques have been utilized in an attempt to enhance MTX clearance and/or minimize severe systemic toxicity. These include extracorporeal removal of MTX by means of peritoneal dialysis, hemodialysis, hemoperfusion, and/or charcoal hemofiltration [<a href="#rid49">49,51,102-108</a>], administration of <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> in conjunction with thymidine [<a href="#rid109">109</a>], use of <a class="drug drug_general" data-topicid="9258" href="/z/d/drug information/9258.html" rel="external">cholestyramine</a> to bind MTX in the gut and aid in MTX clearance [<a href="#rid110">110</a>], and administration of the metabolizing enzyme carboxypeptidase G2 (<a class="drug drug_general" data-topicid="9048" href="/z/d/drug information/9048.html" rel="external">glucarpidase</a>, Voraxaze).</p><p class="headingAnchor" id="H39"><span class="h3">Glucarpidase (carboxypeptidase G2)</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9048" href="/z/d/drug information/9048.html" rel="external">Glucarpidase</a> rescue may be indicated in specific circumstances, as outlined in the table  (<a class="graphic graphic_table graphicRef122543" href="/z/d/graphic/122543.html" rel="external">table 5</a>).</p><p>When renal dysfunction severely compromises clearance of MTX, exogenous administration of the recombinant bacterial enzyme carboxypeptidase G2 (CPDG2, <a class="drug drug_general" data-topicid="9048" href="/z/d/drug information/9048.html" rel="external">glucarpidase</a>, Voraxaze) can rapidly lower serum MTX levels that remain unacceptably high despite adequate hydration and urinary alkalinization [<a href="#rid91">91,111-115</a>]. Glucarpidase metabolizes <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">folic acid</a> (and <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a>) and chemically similar antifolates such as MTX to inactive metabolites. In the case of MTX, the molecule is cleaved at the c-terminal glutamate residue into glutamate and the inactive metabolite DAMPA (2,4-diamino-N-methylpteroic acid). (See <a class="local">'Pharmacokinetics, metabolism, and excretion'</a> above.)</p><p>After a single dose of 50 units per kg by bolus IV injection over five minutes, <a class="drug drug_general" data-topicid="9048" href="/z/d/drug information/9048.html" rel="external">glucarpidase</a> rapidly decreases plasma MTX levels by 98 percent in the first 30 minutes, which in the majority of patients, is sustained [<a href="#rid91">91,112,113,115</a>]. In a series of 43 adult patients treated with glucarpidase for renal dysfunction and delayed MTX elimination, only three required a second dose, which was administered 24 to 48 hours after the first dose [<a href="#rid91">91</a>].</p><p>The importance of early administration of <a class="drug drug_general" data-topicid="9048" href="/z/d/drug information/9048.html" rel="external">glucarpidase</a> was shown in a study of 100 patients who had either a MTX concentration ≥10 micromolar ≥42 hours after the start of the HDMTX infusion or HDMTX-induced renal dysfunction (creatinine ≥1.5 times the upper limit of normal or CrCl ≤60 mL/min and plasma MTX concentration ≥2 standard deviations above the mean ≥12 hours after MTX administration) [<a href="#rid116">116</a>]. All patients received <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> and glucarpidase at one of three dose schedules (single dose, two doses 24 hours apart, or three doses every four hours of 50 U/kg/dose). The initial cohort of 35 patients also received IV thymidine for 48 hours or longer after the last dose of glucarpidase, and subsequent patients received thymidine prior to glucarpidase only if there was &gt;96 hour exposure to high levels of MTX, or if the patients had substantial MTX toxicity at the time of the request for glucarpidase.</p><p><a class="drug drug_general" data-topicid="9048" href="/z/d/drug information/9048.html" rel="external">Glucarpidase</a> was administered at a median of 96 hours in the 44 patients who received thymidine and at 66 hours in the 56 patients who did not receive thymidine. Plasma MTX concentrations decreased by 99 percent within 15 minutes of glucarpidase. Six of the 12 patient deaths were directly attributable to irreversible MTX toxicity. All deaths occurred among the 14 patients with grade 4 toxicity prior to glucarpidase administration, and five of them occurred in patients who received insufficient <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> rescue and delayed administration of glucarpidase after 96 hours.</p><p>Adverse effects are minimal. In a report of data on 290 patients with markedly delayed MTX clearance secondary to renal dysfunction who were treated in two single-arm open-label multicenter trials, the most common adverse reactions that were not hematologic, hepatic, or renal events included paresthesias, flushing, and nausea and vomiting, which each occurred in 2 percent of patients; infusional-related allergic reactions are reported but are uncommon (&lt;1 percent) [<a href="#rid117">117</a>].</p><p><a class="drug drug_general" data-topicid="9048" href="/z/d/drug information/9048.html" rel="external">Glucarpidase</a> was approved in the United States in January 2012 for treatment of toxic MTX plasma concentrations (&gt;1 microM) in patients with delayed MTX clearance due to impaired renal function [<a href="#rid117">117</a>]. The indications for glucarpidase are not well established. Recommendations are available from a year 2018 consensus guideline for use of glucarpidase in patients with HDMTX-induced acute kidney injury and delayed MTX clearance  (<a class="graphic graphic_table graphicRef122543" href="/z/d/graphic/122543.html" rel="external">table 5</a>) [<a href="#rid89">89</a>]. However, clinical interpretation of laboratory results that do not directly correspond to the algorithm is a limitation of its use.</p><p>A clinical decision support tool (available at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fmtxpk.org%2F&amp;token=3a2hYHfNXba05KrINkYwqoWp7Nv002%2F1vq838JQei48%3D&amp;TOPIC_ID=1155" target="_blank">MTXPK.org</a>) has been developed at the Cincinnati Children's Hospital that allows clinicians to utilize individual demographics, serum creatinine, and real-time MTX plasma concentrations to predict the elimination profile for HDMTX and facilitate decision-making for <a class="drug drug_general" data-topicid="9048" href="/z/d/drug information/9048.html" rel="external">glucarpidase</a> [<a href="#rid118">118</a>]. We agree with the use of this clinical decision support tool.</p><p>Importantly, <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> (either the d,l racemic mixture or l-leucovorin [<a class="drug drug_general" data-topicid="10324" href="/z/d/drug information/10324.html" rel="external">LEVOleucovorin</a>]) must be continued for two days beyond <a class="drug drug_general" data-topicid="9048" href="/z/d/drug information/9048.html" rel="external">glucarpidase</a> administration [<a href="#rid49">49,80</a>]. However, because leucovorin is a substrate for glucarpidase, leucovorin doses should not be administered within two hours before or after the dose of glucarpidase.</p><p>MTX concentrations within 48 hours following administration of <a class="drug drug_general" data-topicid="9048" href="/z/d/drug information/9048.html" rel="external">glucarpidase</a> can only be reliably measured by a chromatographic method, as the inactive metabolite that results from cleavage of the MTX molecule, DAMPA, interferes with measurement of MTX levels by immunoassay. (See <a class="local">'Laboratory monitoring during treatment'</a> above.)</p><p class="headingAnchor" id="H2855832456"><span class="h4">Issues related to cost</span><span class="headingEndMark"> — </span>The cost of <a class="drug drug_general" data-topicid="9048" href="/z/d/drug information/9048.html" rel="external">glucarpidase</a> is high enough (Average Wholesale Price $42,000.00 USD per 1000 units) that access and rapid availability are problematic even in large academic medical centers because the drug is used infrequently and not kept "in stock." Most pharmacies need at least a 24 hour notice to procure the agent. This is challenging to the principle of administration as early as possible.</p><p>Given the high cost, there is some intriguing research that perhaps a half dose may be sufficient [<a href="#rid119">119</a>], but this is not yet a standard approach.</p><p class="headingAnchor" id="H3521377"><span class="h4">Rechallenge</span><span class="headingEndMark"> — </span>It is possible to safely resume HDMTX after <a class="drug drug_general" data-topicid="9048" href="/z/d/drug information/9048.html" rel="external">glucarpidase</a> treatment. This was shown in a series of 20 children who received glucarpidase for HDMTX-induced acute kidney injury, 13 of whom were rechallenged after recovery of renal function [<a href="#rid120">120</a>]. Twelve received a reduced dose (33 to 75 percent of the original dose that was associated with acute kidney injury), while one patient with osteosarcoma received the full recommended dose (12 g/m<sup>2</sup>). The maximal serum creatinine after the initial rechallenge was 0.8 mg/dL, and none of the patients required further glucarpidase with subsequent HDMTX courses. These data support the view that use of glucarpidase is associated with complete renal recovery and that resumption of HDMTX is safe after glucarpidase, with close monitoring of renal function and plasma MTX levels.</p><p class="headingAnchor" id="H5926916"><span class="h3">Dialysis</span><span class="headingEndMark"> — </span>Removal of MTX by peritoneal dialysis is ineffective [<a href="#rid121">121</a>], and other dialysis methods are of limited effectiveness. This was illustrated in a review of the efficacy of dialysis-based methods of MTX removal in 49 patients with HDMTX-induced renal dysfunction [<a href="#rid51">51</a>]. The most frequently used methods were hemodialysis (n = 10), high-flux hemodialysis (n = 9), and charcoal hemofiltration (n = 7); 16 patients were treated with multiple modalities. High-flux hemodialysis resulted in the greatest decrease in plasma MTX concentration (median 76 percent) within the shortest period of time (median four hours). However, only three patients had a &gt;90 percent decrease in MTX drug concentration with the use of a single method in one dialysis session.</p><p>A major limitation to the use of dialysis-based methods to remove MTX is the marked rebound in plasma MTX concentration that occurs once dialysis is stopped [<a href="#rid104">104-108</a>]. Further limitations of these methods are the accompanying risks for complications, which can include bleeding, thrombocytopenia, hypokalemia, and severe hypophosphatemia [<a href="#rid102">102,106</a>].</p><p>Overall, these techniques are best utilized temporarily, when combined with higher doses of <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> rescue, while awaiting the initiation of <a class="drug drug_general" data-topicid="9048" href="/z/d/drug information/9048.html" rel="external">glucarpidase</a> therapy.</p><p class="headingAnchor" id="H1044994849"><span class="h3">Thymidine</span><span class="headingEndMark"> — </span>There is no indication for thymidine supplementation. Thymidine supplementation can restore DNA synthesis, even at low serum levels. Unlike <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a>, thymidine does not compete with MTX for uptake into cells. Several older clinical trials and case reports documented the success of thymidine (continuous IV infusion of 8 gm/m<sup>2</sup>/day) as a rescue agent, often in combination with higher doses of leucovorin [<a href="#rid109">109,122-125</a>]. However, thymidine was not effective in the previously discussed series of 100 consecutive patients with HDMTX-induced nephrotoxicity [<a href="#rid116">116</a>].</p><p class="headingAnchor" id="H40"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition, indications, and clearance</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Most clinicians reserve the term high-dose MTX (HDMTX) for doses ≥500 mg/m<sup>2</sup>, as are used for central nervous system (CNS) prophylaxis in patients with leukemia and high-risk lymphoma, and for the treatment of leptomeningeal metastases, primary CNS lymphoma, and osteosarcoma. (See <a class="local">'Definition of high-dose methotrexate'</a> above and <a class="local">'Oncologic indications for high-dose methotrexate'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Almost 90 percent of MTX is excreted unchanged in the urine. When given at high doses, MTX can precipitate in the renal tubules and directly induce tubular injury, especially in the presence of acidic urine and volume depletion. This may severely compromise MTX clearance, resulting in delayed excretion, higher than expected plasma levels, and increased systemic toxicity. (See <a class="local">'Renal toxicity'</a> above and <a class="local">'Pharmacokinetics, metabolism, and excretion'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention of HDMTX toxicity</strong> – The guiding principles for preventing HDMTX toxicity include maintaining urine output and urinary alkalinization; close monitoring of serum creatinine, electrolytes, and plasma MTX concentrations; and pharmacokinetically guided <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> rescue. (See <a class="local">'Practical tips for managing high-dose methotrexate'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pretreatment assessment</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Pretreatment assessment of renal function is needed prior to each dose; if feasible, third-space fluid collections (pleural effusions, ascites) should be drained prior to treatment, as they provide a drug reservoir that prolongs MTX excretion. (See <a class="local">'Pretreatment assessment'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>A number of drugs, including nonsteroidal anti-inflammatory drugs (NSAIDs), <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a>, penicillin-type drugs, <a class="drug drug_general" data-topicid="9812" href="/z/d/drug information/9812.html" rel="external">probenecid</a>, <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>, proton pump inhibitors, tyrosine kinase inhibitors, and possibly <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">levetiracetam</a>, may delay elimination, and their use should be avoided, if possible, during HDMTX treatment. (See <a class="local">'Potential drug-drug-interactions'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Maintaining urinary output and urine alkalinization during HDMTX</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Maintaining adequate hydration and urine output is essential for rapid clearance of HDMTX. Aggressive hydration (2.5 to 3.5 liters of intravenous [IV] fluid/m<sup>2</sup> per day) should start 4 to 12 hours before the MTX infusion is begun and should continue until plasma MTX levels are ≤0.1 microM. (See <a class="local">'Hydration and urinary alkalinization'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Urinary alkalinization, usually with <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">sodium bicarbonate</a> added to each liter of IV fluid hydration (or oral sodium bicarbonate), is required to maintain the urine pH ≥7.0 until plasma MTX levels are below 0.1 microM.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Monitoring creatinine, electrolytes, and plasma MTX levels</strong> – Serum creatinine, electrolytes, and plasma MTX concentrations should be monitored at least daily. (See <a class="local">'Laboratory monitoring during treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">Leucovorin</a><strong> rescue</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">Leucovorin</a> rescue is promptly initiated within 24 to 36 hours of the start of the MTX infusion, with continued leucovorin until MTX plasma levels are &lt;0.1 microM. (See <a class="local">'Leucovorin administration'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">Leucovorin</a> doses are modified if plasma MTX levels are ≥5 to 10 microM at 24 hours, ≥1.0 microM at 48 hours, and/or ≥0.1 microM at 72 hours  (<a class="graphic graphic_table graphicRef64297" href="/z/d/graphic/64297.html" rel="external">table 4</a>). (See <a class="local">'Laboratory monitoring during treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of acute kidney failure during HDMTX</strong> – Even when these preventive guidelines are strictly followed, approximately 2 percent of patients will develop acute kidney failure following HDMTX. Early recognition of renal dysfunction should prompt the following maneuvers (see <a class="local">'Management of patients with renal failure and prolonged high plasma methotrexate levels'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Increase hydration and urinary alkalinization, provided that adequate urine output can be maintained. (See <a class="local">'Augmenting urine output'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Increase doses of d,l <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> or <a class="drug drug_general" data-topicid="10324" href="/z/d/drug information/10324.html" rel="external">LEVOleucovorin</a> based on the measured plasma MTX levels  (<a class="graphic graphic_table graphicRef51155" href="/z/d/graphic/51155.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef64297" href="/z/d/graphic/64297.html" rel="external">table 4</a>). (See <a class="local">'Increased dose and frequency of leucovorin'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9048" href="/z/d/drug information/9048.html" rel="external">Glucarpidase</a> rescue may be indicated in specific circumstances, as outlined in the table  (<a class="graphic graphic_table graphicRef122543" href="/z/d/graphic/122543.html" rel="external">table 5</a>). We utilize a clinical decision support tool (available at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fmtxpk.org%2F&amp;token=3a2hYHfNXba05KrINkYwqoWp7Nv002%2F1vq838JQei48%3D&amp;TOPIC_ID=1155" target="_blank">MTXPK.org</a>) that was developed at the Cincinnati Children's Hospital and allows clinicians to utilize individual demographics, serum creatinine, and real-time MTX plasma concentrations to predict the elimination profile for HDMTX and facilitate decision-making for glucarpidase. (See <a class="local">'Glucarpidase (carboxypeptidase G2)'</a> above.)</p><p></p><p class="bulletIndent2">Administration of <a class="drug drug_general" data-topicid="9048" href="/z/d/drug information/9048.html" rel="external">glucarpidase</a> should optimally occur within 48 to 60 hours from the start of the HDMTX infusion because life-threatening toxicities may not be preventable beyond this time point.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Removal of MTX by dialysis techniques is of limited effectiveness, and dialysis is best utilized temporarily, combined with higher doses of <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> rescue, while awaiting the initiation of <a class="drug drug_general" data-topicid="9048" href="/z/d/drug information/9048.html" rel="external">glucarpidase</a> therapy. (See <a class="local">'Dialysis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">FARBER S, DIAMOND LK. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N Engl J Med 1948; 238:787.</a></li><li><a class="nounderline abstract_t">Yarris JP, Hunter AJ. Roy Hertz, M.D. (1909-2002): the cure of choriocarcinoma and its impact on the development of chemotherapy for cancer. Gynecol Oncol 2003; 89:193.</a></li><li><a class="nounderline abstract_t">Walling J. From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates. Invest New Drugs 2006; 24:37.</a></li><li><a class="nounderline abstract_t">Matherly LH, Goldman DI. Membrane transport of folates. Vitam Horm 2003; 66:403.</a></li><li><a class="nounderline abstract_t">Goldman ID, Matherly LH. The cellular pharmacology of methotrexate. Pharmacol Ther 1985; 28:77.</a></li><li><a class="nounderline abstract_t">Kamen B. Folate and antifolate pharmacology. Semin Oncol 1997; 24:S18.</a></li><li><a class="nounderline abstract_t">Ackland SP, Schilsky RL. High-dose methotrexate: a critical reappraisal. J Clin Oncol 1987; 5:2017.</a></li><li><a class="nounderline abstract_t">Jolivet J, Chabner BA. Intracellular pharmacokinetics of methotrexate polyglutamates in human breast cancer cells. Selective retention and less dissociable binding of 4-NH2-10-CH3-pteroylglutamate4 and 4-NH2-10-CH3-pteroylglutamate5 to dihydrofolate reductase. J Clin Invest 1983; 72:773.</a></li><li><a class="nounderline abstract_t">Treon SP, Chabner BA. Concepts in use of high-dose methotrexate therapy. Clin Chem 1996; 42:1322.</a></li><li><a class="nounderline abstract_t">Bleyer WA. Methotrexate: clinical pharmacology, current status and therapeutic guidelines. Cancer Treat Rev 1977; 4:87.</a></li><li><a class="nounderline abstract_t">Green MR, Chowdhary S, Lombardi KM, et al. Clinical utility and pharmacology of high-dose methotrexate in the treatment of primary CNS lymphoma. Expert Rev Neurother 2006; 6:635.</a></li><li><a class="nounderline abstract_t">Clarke L, Waxman DJ. Human liver folylpolyglutamate synthetase: biochemical characterization and interactions with folates and folate antagonists. Arch Biochem Biophys 1987; 256:585.</a></li><li><a class="nounderline abstract_t">Allegra CJ, Chabner BA, Drake JC, et al. Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J Biol Chem 1985; 260:9720.</a></li><li><a class="nounderline abstract_t">Chabner BA, Allegra CJ, Curt GA, et al. Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest 1985; 76:907.</a></li><li><a class="nounderline abstract_t">Zaharko DS, Fung WP, Yang KH. Relative biochemical aspects of low and high doses of methotrexate in mice. Cancer Res 1977; 37:1602.</a></li><li><a class="nounderline abstract_t">Goulian M, Bleile B, Tseng BY. Methotrexate-induced misincorporation of uracil into DNA. Proc Natl Acad Sci U S A 1980; 77:1956.</a></li><li><a class="nounderline abstract_t">Evans WE, Crom WR, Abromowitch M, et al. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. N Engl J Med 1986; 314:471.</a></li><li><a class="nounderline abstract_t">Fabre I, Fabre G, Goldman ID. Polyglutamylation, an important element in methotrexate cytotoxicity and selectivity in tumor versus murine granulocytic progenitor cells in vitro. Cancer Res 1984; 44:3190.</a></li><li><a class="nounderline abstract_t">Whitehead VM, Shuster JJ, Vuchich MJ, et al. Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts and treatment outcome in children with B-progenitor-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Leukemia 2005; 19:533.</a></li><li><a class="nounderline abstract_t">Masson E, Relling MV, Synold TW, et al. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. J Clin Invest 1996; 97:73.</a></li><li><a class="nounderline abstract_t">Vazquez A, Tedeschi PM, Bertino JR. Overexpression of the mitochondrial folate and glycine-serine pathway: a new determinant of methotrexate selectivity in tumors. Cancer Res 2013; 73:478.</a></li><li><a class="nounderline abstract_t">Goldin A, Venditti JM, Kline I, Mantel N. Eradication of leukaemic cells (L1210) by methotrexate and methotrexate plus citrovorum factor. Nature 1966; 212:1548.</a></li><li><a class="nounderline abstract_t">Matherly LH, Barlowe CK, Goldman ID. Antifolate polyglutamylation and competitive drug displacement at dihydrofolate reductase as important elements in leucovorin rescue in L1210 cells. Cancer Res 1986; 46:588.</a></li><li><a class="nounderline abstract_t">Fry DW, Anderson LA, Borst M, Goldman ID. Analysis of the role of membrane transport and polyglutamation of methotrexate in gut and the Ehrlich tumor in vivo as factors in drug sensitivity and selectivity. Cancer Res 1983; 43:1087.</a></li><li><a class="nounderline abstract_t">Andreassi JL 2nd, Moran RG. Mouse folylpoly-gamma-glutamate synthetase isoforms respond differently to feedback inhibition by folylpolyglutamate cofactors. Biochemistry 2002; 41:226.</a></li><li><a class="nounderline abstract_t">Koizumi S, Curt GA, Fine RL, et al. Formation of methotrexate polyglutamates in purified myeloid precursor cells from normal human bone marrow. J Clin Invest 1985; 75:1008.</a></li><li><a class="nounderline abstract_t">Gorlick R, Goker E, Trippett T, et al. Intrinsic and acquired resistance to methotrexate in acute leukemia. N Engl J Med 1996; 335:1041.</a></li><li><a class="nounderline abstract_t">Zhao R, Goldman ID. Resistance to antifolates. Oncogene 2003; 22:7431.</a></li><li><a class="nounderline abstract_t">Matherly LH, Taub JW, Ravindranath Y, et al. Elevated dihydrofolate reductase and impaired methotrexate transport as elements in methotrexate resistance in childhood acute lymphoblastic leukemia. Blood 1995; 85:500.</a></li><li><a class="nounderline abstract_t">Radtke S, Zolk O, Renner B, et al. Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia. Blood 2013; 121:5145.</a></li><li><a class="nounderline abstract_t">Comandone A, Passera R, Boglione A, et al. High dose methotrexate in adult patients with osteosarcoma: clinical and pharmacokinetic results. Acta Oncol 2005; 44:406.</a></li><li><a class="nounderline abstract_t">Hande KR, Balow JE, Drake JC, et al. Methotrexate and hemodialysis. Ann Intern Med 1977; 87:495.</a></li><li><a class="nounderline abstract_t">Monjanel S, Rigault JP, Cano JP, et al. High-dose methotrexate: preliminary evaluation of a pharmacokinetic approach. Cancer Chemother Pharmacol 1979; 3:189.</a></li><li class="breakAll">Kamen B, Cole P, Bertino J. Folate Antagonists. In: Cancer Medicine, Holland F (Ed), BD Decker, Hamilton, Ontario 2003. p.727.</li><li><a class="nounderline abstract_t">Izraeli S, Vora A, Zwaan CM, Whitlock J. How I treat ALL in Down's syndrome: pathobiology and management. Blood 2014; 123:35.</a></li><li><a class="nounderline abstract_t">Joerger M, Huitema AD, van den Bongard HJ, et al. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. Br J Clin Pharmacol 2006; 62:71.</a></li><li><a class="nounderline abstract_t">Ferrazzini G, Klein J, Sulh H, et al. Interaction between trimethoprim-sulfamethoxazole and methotrexate in children with leukemia. J Pediatr 1990; 117:823.</a></li><li><a class="nounderline abstract_t">Tracy TS, Krohn K, Jones DR, et al. The effects of a salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis. Eur J Clin Pharmacol 1992; 42:121.</a></li><li><a class="nounderline abstract_t">Titier K, Lagrange F, Péhourcq F, et al. Pharmacokinetic interaction between high-dose methotrexate and oxacillin. Ther Drug Monit 2002; 24:570.</a></li><li><a class="nounderline abstract_t">Suzuki K, Doki K, Homma M, et al. Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol 2009; 67:44.</a></li><li><a class="nounderline abstract_t">Santucci R, Levêque D, Lescoute A, et al. Delayed elimination of methotrexate associated with co-administration of proton pump inhibitors. Anticancer Res 2010; 30:3807.</a></li><li><a class="nounderline abstract_t">Pommert L, Liberio N, Ng JS, et al. Concurrent Imatinib Dosing With High-dose Methotrexate Leads to Acute Kidney Injury and Delayed Methotrexate Clearance in Pediatric Patients With Philadelphia Chromosome-positive B-Cell Acute Lymphoblastic Leukemia. J Pediatr Hematol Oncol 2021; 43:e296.</a></li><li><a class="nounderline abstract_t">Ramsey LB, Mizuno T, Vinks AA, O'Brien MM. Delayed methotrexate clearance in patients with acute lymphoblastic leukemia concurrently receiving dasatinib. Pediatr Blood Cancer 2019; 66:e27618.</a></li><li class="breakAll">Summary Safety Review - Levetiracetam and Methotrexate - Assessing the Potential Risk of Drug-Drug Interaction. Available at: http://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/levetiracetam-eng.php (Accessed on October 28, 2016).</li><li><a class="nounderline abstract_t">Bain E, Birhiray RE, Reeves DJ. Drug-drug interaction between methotrexate and levetiracetam resulting in delayed methotrexate elimination. Ann Pharmacother 2014; 48:292.</a></li><li><a class="nounderline abstract_t">Lou U, Kwok J, Nguyen TA, et al. Effect of Levetiracetam on Time to High-Dose Methotrexate Clearance in Patients With Hematologic Malignancies. J Clin Pharmacol 2020; 60:324.</a></li><li><a class="nounderline abstract_t">DeFino CE, Barreto JN, Pawlenty AG, et al. Lack of drug interaction between levetiracetam and high-dose methotrexate in patients with lymphoma. Pharmacotherapy 2021; 41:430.</a></li><li><a class="nounderline abstract_t">American Society of Clinical Oncology, Kris MG, Hesketh PJ, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006; 24:2932.</a></li><li><a class="nounderline abstract_t">Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist 2006; 11:694.</a></li><li class="breakAll">Chu E, Allegra CJ. Antifolates. In: Cancer Chemotherapy and Biotherapy, 2nd ed, Chabner B, Longo D (Eds), Lippincott-Raven, Philadelphia 1996. p.130.</li><li><a class="nounderline abstract_t">Widemann BC, Balis FM, Kempf-Bielack B, et al. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. Cancer 2004; 100:2222.</a></li><li><a class="nounderline abstract_t">Amitai I, Rozovski U, El-Saleh R, et al. Risk factors for high-dose methotrexate associated acute kidney injury in patients with hematological malignancies. Hematol Oncol 2020; 38:584.</a></li><li><a class="nounderline abstract_t">Hansen HH, Selawry OS, Holland JF, McCall CB. The variability of individual tolerance to methotrexate in cancer patients. Br J Cancer 1971; 25:298.</a></li><li><a class="nounderline abstract_t">Stoller RG, Kaplan HG, Cummings FJ, Calabresi P. A clinical and pharmacological study of high-dose methotrexate with minimal leucovorin rescue. Cancer Res 1979; 39:908.</a></li><li><a class="nounderline abstract_t">Alkins SA, Byrd JC, Morgan SK, et al. Anaphylactoid reactions to methotrexate. Cancer 1996; 77:2123.</a></li><li><a class="nounderline abstract_t">Wolfrom C, Hartmann R, Fengler R, et al. Randomized comparison of 36-hour intermediate-dose versus 4-hour high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukemia. J Clin Oncol 1993; 11:827.</a></li><li><a class="nounderline abstract_t">Borsi JD, Schuler D, Moe PJ. Methotrexate administered by 6-h and 24-h infusion: a pharmacokinetic comparison. Cancer Chemother Pharmacol 1988; 22:33.</a></li><li><a class="nounderline abstract_t">Goorin AM, Abelson HT, Frei E 3rd. Osteosarcoma: fifteen years later. N Engl J Med 1985; 313:1637.</a></li><li><a class="nounderline abstract_t">Anderson PM, Pearson M. Novel therapeutic approaches in pediatric and young adult sarcomas. Curr Oncol Rep 2006; 8:310.</a></li><li class="breakAll">Aronoff GM, Bennett WM, Berns JS, et al. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th ed, American College of Physicians, 2007.</li><li><a class="nounderline abstract_t">Janus N, Thariat J, Boulanger H, et al. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. Ann Oncol 2010; 21:1395.</a></li><li><a class="nounderline abstract_t">Kintzel PE, Dorr RT. Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev 1995; 21:33.</a></li><li><a class="nounderline abstract_t">Gerber DE, Grossman SA, Batchelor T, Ye X. Calculated versus measured creatinine clearance for dosing methotrexate in the treatment of primary central nervous system lymphoma. Cancer Chemother Pharmacol 2007; 59:817.</a></li><li><a class="nounderline abstract_t">Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000; 18:547.</a></li><li><a class="nounderline abstract_t">Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function--measured and estimated glomerular filtration rate. N Engl J Med 2006; 354:2473.</a></li><li><a class="nounderline abstract_t">Marx GM, Blake GM, Galani E, et al. Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients. Ann Oncol 2004; 15:291.</a></li><li class="breakAll">NCCN Chemotherapy Order Templates (NCCN Templates). Appendix B. Carboplatin Dosing in Adults. Available at: https://www.nccn.org/docs/default-source/clinical/order-templates/appendix_b.pdf?sfvrsn=6286822e_6 (Accessed on April 22, 2022).</li><li><a class="nounderline abstract_t">Zhu JJ, Gerstner ER, Engler DA, et al. High-dose methotrexate for elderly patients with primary CNS lymphoma. Neuro Oncol 2009; 11:211.</a></li><li><a class="nounderline abstract_t">Martinez-Calle N, Isbell LK, Cwynarski K, Schorb E. Treatment of elderly patients with primary CNS lymphoma. Ann Lymphoma 2021; 5:2.</a></li><li><a class="nounderline abstract_t">Jahnke K, Korfel A, Martus P, et al. High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma. Ann Oncol 2005; 16:445.</a></li><li><a class="nounderline abstract_t">Wang Y, Wei L, Guan Y, et al. Diabetes is a risk factor for high-dose methotrexate-associated AKI in lymphoma patients. Ren Fail 2020; 42:1111.</a></li><li><a class="nounderline abstract_t">Floyd J, Mirza I, Sachs B, Perry MC. Hepatotoxicity of chemotherapy. Semin Oncol 2006; 33:50.</a></li><li><a class="nounderline abstract_t">Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2021; 39:2037.</a></li><li><a class="nounderline abstract_t">Heisler RD, Kelly JJ, Abedinzadegan Abdi S, et al. Evaluation of an oral sodium bicarbonate protocol for high-dose methotrexate urine alkalinization. Support Care Cancer 2022; 30:1273.</a></li><li><a class="nounderline abstract_t">Sirotnak FM, Moccio DM, Dorick DM. Optimization of high-dose methotrexate with leucovorin rescue therapy in the L1210 leukemia and sarcoma 180 murine tumor models. Cancer Res 1978; 38:345.</a></li><li><a class="nounderline abstract_t">Kawaguchi S, Fujiwara SI, Murahashi R, et al. Risk factors for high-dose methotrexate-induced nephrotoxicity. Int J Hematol 2021; 114:79.</a></li><li><a class="nounderline abstract_t">Santucci R, Levêque D, Herbrecht R. Cola beverage and delayed elimination of methotrexate. Br J Clin Pharmacol 2010; 70:762.</a></li><li><a class="nounderline abstract_t">Howard SC, McCormick J, Pui CH, et al. Preventing and Managing Toxicities of High-Dose Methotrexate. Oncologist 2016; 21:1471.</a></li><li><a class="nounderline abstract_t">Stoller RG, Hande KR, Jacobs SA, et al. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med 1977; 297:630.</a></li><li><a class="nounderline abstract_t">Hempel G, Lingg R, Boos J. Interactions of carboxypeptidase G2 with 6S-leucovorin and 6R-leucovorin in vitro: implications for the application in case of methotrexate intoxications. Cancer Chemother Pharmacol 2005; 55:347.</a></li><li><a class="nounderline abstract_t">Straw JA, Szapary D, Wynn WT. Pharmacokinetics of the diastereoisomers of leucovorin after intravenous and oral administration to normal subjects. Cancer Res 1984; 44:3114.</a></li><li><a class="nounderline abstract_t">McGuire BW, Sia LL, Haynes JD, et al. Absorption kinetics of orally administered leucovorin calcium. NCI Monogr 1987; :47.</a></li><li><a class="nounderline abstract_t">Isacoff WH, Eilber F, Tabbarah H, et al. Phase II clinical trial with high-dose methotrexate therapy and citrovorum factor rescue. Cancer Treat Rep 1978; 62:1295.</a></li><li><a class="nounderline abstract_t">Evans WE, Pratt CB, Taylor RH, et al. Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients. Cancer Chemother Pharmacol 1979; 3:161.</a></li><li><a class="nounderline abstract_t">Nirenberg A, Mosende C, Mehta BM, et al. High-dose methotrexate with citrovorum factor rescue: predictive value of serum methotrexate concentrations and corrective measures to avert toxicity. Cancer Treat Rep 1977; 61:779.</a></li><li><a class="nounderline abstract_t">Pitman SW, Parker LM, Tattersall MH, et al. Clinical trial of high-dose methotrexate (NSC 740) with citrovorum factor (NSC 3590) - toxicologic and therapeutic observations. Cancer Chemother Rep 1975; 6:43.</a></li><li><a class="nounderline abstract_t">Kerr IG, Jolivet J, Collins JM, et al. Test dose for predicting high-dose methotrexate infusions. Clin Pharmacol Ther 1983; 33:44.</a></li><li><a class="nounderline abstract_t">Joannon P, Oviedo I, Campbell M, Tordecilla J. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance. Pediatr Blood Cancer 2004; 43:17.</a></li><li><a class="nounderline abstract_t">Ramsey LB, Balis FM, O'Brien MM, et al. Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance. Oncologist 2018; 23:52.</a></li><li><a class="nounderline abstract_t">Skärby T, Jönsson P, Hjorth L, et al. High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL). Cancer Chemother Pharmacol 2003; 51:311.</a></li><li><a class="nounderline abstract_t">Schwartz S, Borner K, Müller K, et al. Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy. Oncologist 2007; 12:1299.</a></li><li><a class="nounderline abstract_t">Rosen G, Caparros B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 1982; 49:1221.</a></li><li><a class="nounderline abstract_t">Djerassi I, Kim JS, Nayak N, et al. New "rescue" with massive doses of citrovorum factor for potentially lethal methotrexate toxicity. Cancer Treat Rep 1977; 61:749.</a></li><li><a class="nounderline abstract_t">Bleyer WA. The clinical pharmacology of methotrexate: new applications of an old drug. Cancer 1978; 41:36.</a></li><li><a class="nounderline abstract_t">Cerminara Z, Duffy A, Nishioka J, et al. A single center retrospective analysis of a protocol for high-dose methotrexate and leucovorin rescue administration. J Oncol Pharm Pract 2019; 25:76.</a></li><li><a class="nounderline abstract_t">Sasaki K, Tanaka J, Murakami T, et al. Reduced citrovorum factor rescue for high-dose methotrexate therapy in childhood malignancies. Cancer Drug Deliv 1985; 2:77.</a></li><li><a class="nounderline abstract_t">Cohen IJ. Progression of osteosarcoma after high-dose methotrexate: over-rescue by folinic acid. Pediatr Hematol Oncol 2003; 20:579.</a></li><li><a class="nounderline abstract_t">Skärby TV, Anderson H, Heldrup J, et al. High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemia. Leukemia 2006; 20:1955.</a></li><li><a class="nounderline abstract_t">Cohen IJ. Defining the appropriate dosage of folinic acid after high-dose methotrexate for childhood acute lymphatic leukemia that will prevent neurotoxicity without rescuing malignant cells in the central nervous system. J Pediatr Hematol Oncol 2004; 26:156.</a></li><li><a class="nounderline abstract_t">Pinedo HM, Zaharko DS, Bull JM, Chabner BA. The reversal of methotrexate cytotoxicity to mouse bone marrow cells by leucovorin and nucleosides. Cancer Res 1976; 36:4418.</a></li><li><a class="nounderline abstract_t">Flombaum CD, Meyers PA. High-dose leucovorin as sole therapy for methotrexate toxicity. J Clin Oncol 1999; 17:1589.</a></li><li><a class="nounderline abstract_t">Saland JM, Leavey PJ, Bash RO, et al. Effective removal of methotrexate by high-flux hemodialysis. Pediatr Nephrol 2002; 17:825.</a></li><li><a class="nounderline abstract_t">Wall SM, Johansen MJ, Molony DA, et al. Effective clearance of methotrexate using high-flux hemodialysis membranes. Am J Kidney Dis 1996; 28:846.</a></li><li><a class="nounderline abstract_t">Bouffet E, Frappaz D, Laville M, et al. Charcoal haemoperfusion and methotrexate toxicity. Lancet 1986; 1:1497.</a></li><li><a class="nounderline abstract_t">Greil J, Wyss PA, Ludwig K, et al. Continuous plasma resin perfusion for detoxification of methotrexate. Eur J Pediatr 1997; 156:533.</a></li><li><a class="nounderline abstract_t">Relling MV, Stapleton FB, Ochs J, et al. Removal of methotrexate, leucovorin, and their metabolites by combined hemodialysis and hemoperfusion. Cancer 1988; 62:884.</a></li><li><a class="nounderline abstract_t">Kawabata K, Makino H, Nagake Y, et al. A case of methotrexate-induced acute renal failure successfully treated with plasma perfusion and sequential hemodialysis. Nephron 1995; 71:233.</a></li><li><a class="nounderline abstract_t">Jambou P, Levraut J, Favier C, et al. Removal of methotrexate by continuous venovenous hemodiafiltration. Contrib Nephrol 1995; 116:48.</a></li><li><a class="nounderline abstract_t">van den Bongard HJ, Mathĵt RA, Boogerd W, et al. Successful rescue with leucovorin and thymidine in a patient with high-dose methotrexate induced acute renal failure. Cancer Chemother Pharmacol 2001; 47:537.</a></li><li><a class="nounderline abstract_t">Merino-Sanjuán M, Carrera A, Monte E, Jiménez-Torres NV. Adsorption of methotrexate and calcium leucovorin onto cholestyramine in vitro. Int J Pharm 2004; 278:283.</a></li><li><a class="nounderline abstract_t">Krause AS, Weihrauch MR, Bode U, et al. Carboxypeptidase-G2 rescue in cancer patients with delayed methotrexate elimination after high-dose methotrexate therapy. Leuk Lymphoma 2002; 43:2139.</a></li><li><a class="nounderline abstract_t">Widemann BC, Balis FM, Murphy RF, et al. Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction. J Clin Oncol 1997; 15:2125.</a></li><li><a class="nounderline abstract_t">Buchen S, Ngampolo D, Melton RG, et al. Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure. Br J Cancer 2005; 92:480.</a></li><li><a class="nounderline abstract_t">DeAngelis LM, Tong WP, Lin S, et al. Carboxypeptidase G2 rescue after high-dose methotrexate. J Clin Oncol 1996; 14:2145.</a></li><li><a class="nounderline abstract_t">Widemann BC, Schwartz S, Jayaprakash N, et al. Efficacy of glucarpidase (carboxypeptidase g2) in patients with acute kidney injury after high-dose methotrexate therapy. Pharmacotherapy 2014; 34:427.</a></li><li><a class="nounderline abstract_t">Widemann BC, Balis FM, Kim A, et al. Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome. J Clin Oncol 2010; 28:3979.</a></li><li class="breakAll">VORAXAZE (glucarpidase). For Injection, for intravenous use. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125327lbl.pdf?et_cid=28599956&amp;et_rid=463638624&amp;linkid=http%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2012%2f125327lbl.pdf (Accessed on January 18, 2012).</li><li><a class="nounderline abstract_t">Taylor ZL, Mizuno T, Punt NC, et al. MTXPK.org: A Clinical Decision Support Tool Evaluating High-Dose Methotrexate Pharmacokinetics to Inform Post-Infusion Care and Use of Glucarpidase. Clin Pharmacol Ther 2020; 108:635.</a></li><li><a class="nounderline abstract_t">Heuschkel S, Kretschmann T, Teipel R, et al. Half-dose glucarpidase as efficient rescue for toxic methotrexate levels in patients with acute kidney injury. Cancer Chemother Pharmacol 2022; 89:41.</a></li><li><a class="nounderline abstract_t">Christensen AM, Pauley JL, Molinelli AR, et al. Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients. Cancer 2012; 118:4321.</a></li><li><a class="nounderline abstract_t">Ahmad S, Shen FH, Bleyer WA. Methotrexate-induced renal failure and ineffectiveness of peritoneal dialysis. Arch Intern Med 1978; 138:1146.</a></li><li><a class="nounderline abstract_t">Grem JL, King SA, Sorensen JM, Christian MC. Clinical use of thymidine as a rescue agent from methotrexate toxicity. Invest New Drugs 1991; 9:281.</a></li><li><a class="nounderline abstract_t">Abelson HT, Fosburg MT, Beardsley GP, et al. Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine. J Clin Oncol 1983; 1:208.</a></li><li><a class="nounderline abstract_t">Ensminger WD, Frei E 3rd. The prevention of methotrexate toxicity by thymidine infusions in humans. Cancer Res 1977; 37:1857.</a></li><li><a class="nounderline abstract_t">Howell SB, Herbst K, Boss GR, Frei E 3rd. Thymidine requirements for the rescue of patients treated with high-dose methotrexate. Cancer Res 1980; 40:1824.</a></li></ol></div><div id="topicVersionRevision">Topic 1155 Version 42.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18860765" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12765173" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Roy Hertz, M.D. (1909-2002): the cure of choriocarcinoma and its impact on the development of chemotherapy for cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16380836" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12852262" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Membrane transport of folates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2414788" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The cellular pharmacology of methotrexate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9420019" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Folate and antifolate pharmacology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3316519" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : High-dose methotrexate: a critical reappraisal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6193143" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Intracellular pharmacokinetics of methotrexate polyglutamates in human breast cancer cells. Selective retention and less dissociable binding of 4-NH2-10-CH3-pteroylglutamate4 and 4-NH2-10-CH3-pteroylglutamate5 to dihydrofolate reductase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8697606" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Concepts in use of high-dose methotrexate therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/329989" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Methotrexate: clinical pharmacology, current status and therapeutic guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16734512" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Clinical utility and pharmacology of high-dose methotrexate in the treatment of primary CNS lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3619447" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Human liver folylpolyglutamate synthetase: biochemical characterization and interactions with folates and folate antagonists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2410416" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2413074" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Polyglutamation of methotrexate. Is methotrexate a prodrug?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/870175" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Relative biochemical aspects of low and high doses of methotrexate in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6929529" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Methotrexate-induced misincorporation of uracil into DNA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3456079" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6204743" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Polyglutamylation, an important element in methotrexate cytotoxicity and selectivity in tumor versus murine granulocytic progenitor cells in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15716987" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts and treatment outcome in children with B-progenitor-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8550853" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23135910" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Overexpression of the mitochondrial folate and glycine-serine pathway: a new determinant of methotrexate selectivity in tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21105503" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Eradication of leukaemic cells (L1210) by methotrexate and methotrexate plus citrovorum factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2416428" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Antifolate polyglutamylation and competitive drug displacement at dihydrofolate reductase as important elements in leucovorin rescue in L1210 cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6186369" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Analysis of the role of membrane transport and polyglutamation of methotrexate in gut and the Ehrlich tumor in vivo as factors in drug sensitivity and selectivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11772020" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Mouse folylpoly-gamma-glutamate synthetase isoforms respond differently to feedback inhibition by folylpolyglutamate cofactors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2579975" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Formation of methotrexate polyglutamates in purified myeloid precursor cells from normal human bone marrow.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8793930" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Intrinsic and acquired resistance to methotrexate in acute leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14576850" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Resistance to antifolates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7812005" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Elevated dihydrofolate reductase and impaired methotrexate transport as elements in methotrexate resistance in childhood acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23652803" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16120550" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : High dose methotrexate in adult patients with osteosarcoma: clinical and pharmacokinetic results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/907253" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Methotrexate and hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/527209" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : High-dose methotrexate: preliminary evaluation of a pharmacokinetic approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/527209" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : High-dose methotrexate: preliminary evaluation of a pharmacokinetic approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24235135" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : How I treat ALL in Down's syndrome: pathobiology and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16842380" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2231218" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Interaction between trimethoprim-sulfamethoxazole and methotrexate in children with leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1618240" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The effects of a salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12142645" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Pharmacokinetic interaction between high-dose methotrexate and oxacillin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19076159" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20944174" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Delayed elimination of methotrexate associated with co-administration of proton pump inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32398599" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Concurrent Imatinib Dosing With High-dose Methotrexate Leads to Acute Kidney Injury and Delayed Methotrexate Clearance in Pediatric Patients With Philadelphia Chromosome-positive B-Cell Acute Lymphoblastic Leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30677213" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Delayed methotrexate clearance in patients with acute lymphoblastic leukemia concurrently receiving dasatinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30677213" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Delayed methotrexate clearance in patients with acute lymphoblastic leukemia concurrently receiving dasatinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24259648" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Drug-drug interaction between methotrexate and levetiracetam resulting in delayed methotrexate elimination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31729053" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Effect of Levetiracetam on Time to High-Dose Methotrexate Clearance in Patients With Hematologic Malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33655525" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Lack of drug interaction between levetiracetam and high-dose methotrexate in patients with lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16717289" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16794248" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Understanding and managing methotrexate nephrotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16794248" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Understanding and managing methotrexate nephrotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15139068" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32506594" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Risk factors for high-dose methotrexate associated acute kidney injury in patients with hematological malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4256007" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The variability of individual tolerance to methotrexate in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/311683" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : A clinical and pharmacological study of high-dose methotrexate with minimal leucovorin rescue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8640680" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Anaphylactoid reactions to methotrexate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8487046" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Randomized comparison of 36-hour intermediate-dose versus 4-hour high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3260832" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Methotrexate administered by 6-h and 24-h infusion: a pharmacokinetic comparison.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3906399" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Osteosarcoma: fifteen years later.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17254532" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Novel therapeutic approaches in pediatric and young adult sarcomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17254532" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Novel therapeutic approaches in pediatric and young adult sarcomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20118214" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7859226" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16972068" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Calculated versus measured creatinine clearance for dosing methotrexate in the treatment of primary central nervous system lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10653870" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16760447" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Assessing kidney function--measured and estimated glomerular filtration rate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14760124" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14760124" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18757775" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : High-dose methotrexate for elderly patients with primary CNS lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Treatment of elderly patients with primary CNS lymphoma</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15653703" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33164656" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Diabetes is a risk factor for high-dose methotrexate-associated AKI in lymphoma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16473644" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Hepatotoxicity of chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33939491" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34471970" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Evaluation of an oral sodium bicarbonate protocol for high-dose methotrexate urine alkalinization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/304375" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Optimization of high-dose methotrexate with leucovorin rescue therapy in the L1210 leukemia and sarcoma 180 murine tumor models.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33743109" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Risk factors for high-dose methotrexate-induced nephrotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21545633" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Cola beverage and delayed elimination of methotrexate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27496039" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Preventing and Managing Toxicities of High-Dose Methotrexate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/302412" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15723260" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Interactions of carboxypeptidase G2 with 6S-leucovorin and 6R-leucovorin in vitro: implications for the application in case of methotrexate intoxications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6609768" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Pharmacokinetics of the diastereoisomers of leucovorin after intravenous and oral administration to normal subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3501546" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Absorption kinetics of orally administered leucovorin calcium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/356984" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Phase II clinical trial with high-dose methotrexate therapy and citrovorum factor rescue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/316744" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/302143" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : High-dose methotrexate with citrovorum factor rescue: predictive value of serum methotrexate concentrations and corrective measures to avert toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Clinical trial of high-dose methotrexate (NSC 740) with citrovorum factor (NSC 3590) - toxicologic and therapeutic observations</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6848298" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Test dose for predicting high-dose methotrexate infusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15170885" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29079637" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12721759" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18055849" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6174200" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/301784" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : New "rescue" with massive doses of citrovorum factor for potentially lethal methotrexate toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/342086" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : The clinical pharmacology of methotrexate: new applications of an old drug.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28942720" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : A single center retrospective analysis of a protocol for high-dose methotrexate and leucovorin rescue administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3876873" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Reduced citrovorum factor rescue for high-dose methotrexate therapy in childhood malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14578026" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Progression of osteosarcoma after high-dose methotrexate: over-rescue by folinic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16990760" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15125607" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Defining the appropriate dosage of folinic acid after high-dose methotrexate for childhood acute lymphatic leukemia that will prevent neurotoxicity without rescuing malignant cells in the central nervous system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1087180" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : The reversal of methotrexate cytotoxicity to mouse bone marrow cells by leucovorin and nucleosides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10334548" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : High-dose leucovorin as sole therapy for methotrexate toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12376811" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Effective removal of methotrexate by high-flux hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8957036" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Effective clearance of methotrexate using high-flux hemodialysis membranes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2873302" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Charcoal haemoperfusion and methotrexate toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9243235" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Continuous plasma resin perfusion for detoxification of methotrexate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3261621" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Removal of methotrexate, leucovorin, and their metabolites by combined hemodialysis and hemoperfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8569964" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : A case of methotrexate-induced acute renal failure successfully treated with plasma perfusion and sequential hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8529381" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Removal of methotrexate by continuous venovenous hemodiafiltration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11459208" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Successful rescue with leucovorin and thymidine in a patient with high-dose methotrexate induced acute renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15196633" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Adsorption of methotrexate and calcium leucovorin onto cholestyramine in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12533039" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Carboxypeptidase-G2 rescue in cancer patients with delayed methotrexate elimination after high-dose methotrexate therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9164227" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15668713" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8683248" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Carboxypeptidase G2 rescue after high-dose methotrexate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24132809" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Efficacy of glucarpidase (carboxypeptidase g2) in patients with acute kidney injury after high-dose methotrexate therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20679598" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20679598" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32558929" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : MTXPK.org: A Clinical Decision Support Tool Evaluating High-Dose Methotrexate Pharmacokinetics to Inform Post-Infusion Care and Use of Glucarpidase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34669022" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Half-dose glucarpidase as efficient rescue for toxic methotrexate levels in patients with acute kidney injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22252903" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/666479" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Methotrexate-induced renal failure and ineffectiveness of peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1838364" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Clinical use of thymidine as a rescue agent from methotrexate toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6607976" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/870189" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : The prevention of methotrexate toxicity by thymidine infusions in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7371013" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Thymidine requirements for the rescue of patients treated with high-dose methotrexate.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
